

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 October 2002 (24.10.2002)

PCT

(10) International Publication Number
WO 02/083888 A2

(51) International Patent Classification: **C12N 15/00**

(21) International Application Number: PCT/EP02/04322

(22) International Filing Date: 18 April 2002 (18.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01201407.2 18 April 2001 (18.04.2001) EP

(71) Applicant (for all designated States except US):
**VLAAMS INTERUNIVERSITAIR INSTITUUT
VOOR BIOTECHNOLOGIE VZW** [BE/BE]; Rijviss-
chestraat 120, B-9052 Zwijnaarde (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GOOSSENS, Alain**
[BE/BE]; Markt 36, B-9160 Lokeren (BE). **INZÉ, Dirk**
[BE/BE]; Gustaaf Driesstraat 18, B-9310 Moorsel - Aalst
(BE).

(74) Common Representative: **VLAAMS INTERUNIVER-
SITAIR INSTITUUT VOOR BIOTECHNOLOGIE
VZW**; Rijvisschestraat 120, B-9052 Zwijnaarde (BE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: THE USE OF GENES ENCODING MEMBRANE TRANSPORTER PUMPS TO STIMULATE THE PRODUCTION OF SECONDARY METABOLITES IN BIOLOGICAL CELLS

(57) Abstract: The current invention relates to the field of secondary metabolite production in plants and plant cell cultures. More specifically, the invention relates to the use of transporters and more particularly ABC-transporters to enhance the production and/or secretion of secondary metabolites in plants and plant cell cultures.

WO 02/083888 A2



The use of genes encoding membrane transporter pumps to stimulate the production of secondary metabolites in biological cells

Field of the invention

- 5 The current invention relates to the field of secondary metabolite production in plants and plant cell cultures. More specifically, the invention relates to the use of transporters and more particularly ABC-transporters to enhance the production and/or secretion of secondary metabolites in plants and plant cell cultures.

Introduction to the invention

- 10 Higher plants are able to produce a large number of small-molecular-weight compounds with very complex structures. These compounds, called secondary metabolites, play for example a role in the resistance against pests and diseases, attraction of pollinators and interaction with symbiotic microorganisms. Besides the
- 15 importance for the plant itself, secondary metabolites are of great interest because they determine the quality of food (colour, taste, aroma) and ornamental plants (flower colour, smell). A number of secondary metabolites isolated from plants are commercially available as fine chemicals, for example, drugs, dyes, flavours, fragrances and even pesticides. In addition, various health improving effects and
- 20 disease preventing activities of secondary metabolites have been discovered, such as anti-oxidative and anti-metastatic-lowering properties (e.g. vinblastine, taxol). Although about 100.000 plant secondary metabolites are already known, only a small percentage of all plants have been studied to some extent for the presence of secondary metabolites. It is expected that interest in such metabolites will continue to
- 25 grow as e.g. plant sources of new and useful drugs are discovered. Some of these valuable phytochemicals are quite expensive because they are only produced at extremely low levels in plants. Very little is known about the biosynthesis of secondary metabolites in plants. However, some recently elucidated biosynthetic pathways of secondary metabolites are long and complicated requiring multiple enzymatic steps to
- 30 produce the desired end product. Most often, the alternative of producing these secondary metabolites through chemical synthesis is complicated due to a large number of asymmetric carbons and in most cases chemical synthesis is not economically feasible.

The recovery of valuable secondary metabolites is mostly achieved through extraction and purification (generally at low yields) of imported, sometimes exotic, plant biomasses, whose reproductive agriculture and secure long term supply are often very difficult, if not impossible to guarantee. The problems of obtaining useful metabolites from natural sources may potentially be circumvented by cell culture. The culture of plant cells has been explored since the 1960's as a viable alternative for the production of complex phytochemicals of industrial interest. Although plant cell cultures might be somewhat sensitive for shear forces, many cultures can be grown in large bioreactors without difficulty. For example, the use of large-scale plant cell cultures in bioreactors for the production of alkaloids has been extensively studied (Verpoorte et al. (1999) *Biotechnol. Lett.* 21, 467). Since it has been observed that undifferentiated cultures such as callus and cell suspension cultures produce only very low levels of secondary metabolites one tends to use differentiated plant cell cultures such as root- and hairy root-culture. For example, tropane alkaloids that are only scarcely synthesized in undifferentiated cells are produced at relatively high levels in cultured roots. Despite the promising features and developments, the production of plant-derived pharmaceuticals by plant cell cultures has not been fully commercially exploited. The main reasons for this reluctance shown by industry to produce secondary metabolites by means of cell cultures, compared to the conventional extraction of whole plant material, are economical ones based on the slow growth and the low production levels of secondary metabolites by such plant cell cultures. Important causes are the toxicity of such compounds to the plant cell, and the role of catabolism of the secondary metabolites. Another important problem is that secondary metabolites are mostly retained intracellularly complicating the downstream processing and purification. Indeed, often laborious extraction schemes have to be developed for each specific secondary metabolite of interest.

It is an objective of the current invention to provide a solution to these problems. The invention aims primarily at using genes encoding ABC-transporters to enhance the production of secondary metabolites in plant cell cultures. ABC-transporters are well known in the field of cancer therapy as molecular 'pumps' in tumour-cell membranes that actively expel chemotherapy drugs from the interior of the cells. This allows tumour cells to avoid the toxic effects of the drug or molecular processes within the nucleus or the cytoplasm. The two pumps commonly found to confer chemoresistance in cancer are P-glycoprotein and the so-called multidrug resistance-associated protein

(MRP). In addition, ABC-transporters have been used in plants as a selection marker (WO 99/10514) and for the protection of plants for the detrimental effects of certain exogenously added xenobiotics (WO 00/18886, Muhitch J.M. et al. (2000) *Plant Science*, 157, 201). In US patent 6,166,290 it is shown that the use of ABC-transporters in plants can be used to stimulate remediation, to strengthen the disease response and to modulate plant pigmentation. It has however never been shown in the art that ABC-transporters can be used to enhance the level of secondary metabolites made in plant cell cultures neither has it been shown that ABC-transporters can be used to stimulate the secretion of endogenously synthesized secondary metabolites from the inside of plant cells to the extracellular space.

Legends of Figures

Fig. 1: Plasmid map of the pK7WGD2 binary vector.

Fig. 2: Hyoscyamine-induced cell death in transformed BY-2 cells.

Three-day old transformed BY-2 cell cultures were incubated in the absence (CON) or presence (HYO) of 30 mM hyoscyamin for 24 hours. Cell death was assayed at two timepoints (6 hours and 24 hours) by Evans blue staining and is indicated as the fold increase in optical density at OD₆₀₀ relative to the value at the start of the experiment. Values are the mean of three independent experiments. GUS, US50, W303 and AT represent BY-2 cell lines transformed with pK7WGD2-GUS, pK7WGD2-ScPDR5-US50, pK7WGD2-ScPDR5-W303 and pK7WGD2-AtPDR1 respectively.

Fig. 3 : *HmPDR1* expression is induced by CdCl₂.

Quantitative RT-PCR analysis of *HmPDR1* in total RNA from *H. muticus* hairy roots treated with 1mM CdCl₂ or H₂O as a control. Ethidium bromide-stained rRNA is used as a control. The fold increase in the ratio of *HmPDR1* transcript to rRNA fluorescence, relative to the value at timepoint zero, is given below the panels. Time after elicitation is indicated in hours.

Aims and detailed description of the invention

The human species has always been interested in plant secondary metabolites for flavourings for food, perfumes, pigments for artwork and clothing, and tools to achieve

spiritual enlightenment. Furthermore, plant derived drugs are among the oldest drugs in medicine. Many plants belonging to, for example, the *Solanaceae* family have been used for centuries because of their active substances: hyoscyamine and scopolamine. Also other *Solanaceae* plants belonging to the genera *Atropa*, *Datura*, *Duboisia* and *Scopolia* produce these valuable alkaloids. In medicine they find important applications in ophthalmology, anaesthesia, and in the treatment of cardiac and gastrointestinal diseases. In addition to their peripheral anticholinergic effects they also act on the central nervous system and are used to relieve the symptoms of Parkinson's disease, and as antidotes for the anticholinesterases such as organophosphates. Cocaine, which has strong stimulant effects on the central nervous system and is used as a topical anaesthetic, is also a tropane alkaloid but is found outside *Solanaceae* in *Erythroxylum coca*. Although a lot of information is available on the pharmacological effects of tropane alkaloids, surprisingly little is known about how the plants synthesize these substances and almost nothing is known about how this synthesis is regulated. Progress in the elucidation of the biosynthetic pathways of plant secondary products has long been hampered by lack of good model systems. In the past two decades plant cell cultures have proven to be invaluable tools in the investigation of plant secondary metabolite biosynthetic pathways. Plant cell and tissue cultures have also been widely used in order to obtain alternative production systems of tropane alkaloids as described above. The main problem has usually been a lack of a sufficient amount of alkaloids and/or instability of the production. Many cultures have shown a decrease in productivity with time. Current approaches to resolve some of the above described problems comprise: (1) the optimisation of the growth conditions of plant cell cultures (US 6,069,009), (2) the metabolic engineering of secondary metabolism by overexpression of regulatory genes (e.g. transcription factors) that induce the pathway (WO 00/46383) and (3) the stimulation of secondary metabolism by the use of elicitors (US 5,552,307). In the present invention we have identified an important bottleneck for the production of secondary metabolites in plants and plant cell cultures. We have found that production of secondary metabolites in plants and plant cell cultures can be enhanced by the transformation of a gene encoding a transporter to the plants or plant cells producing the desired secondary metabolite. Sometimes the slow growth of plant cells producing secondary metabolites is due to the toxicity of the metabolites which are produced inside the plant cells. We have shown that the toxicity can to a large extent be reduced by the transformation of a gene encoding a transporter to the plant

cells producing the desired secondary metabolite. Consequently, due to the reduction of the toxicity there is a higher growth rate of the transformed plant cell culture.

- The present invention accordingly provides in one embodiment a method for inducing or enhancing the production or the secretion of at least one secondary metabolite in
- 5 biological cells by transformation of said biological cells with an expression vector comprising an expression cassette that further comprises a gene coding for a transporter. With "at least one secondary metabolite" it is meant related structures of secondary metabolites and intermediates or precursors thereof. Said biological cells can be plant cells, fungal cells, bacteria cells, algae cells and/or animal cells. A
- 10 "transporter" is a protein capable of interacting with at least one specific secondary metabolite and transporting said metabolite across a membrane wherein said membrane comprises the vacuolar membrane (tonoplast), or chloroplast membrane or plasmamembrane. Said transporter gene can be heterologous or homologous to the biological cell.
- 15 "Expression cassettes", of the present invention are generally DNA constructs preferably including (5' to 3' in the direction of transcription): a promoter region, a gene encoding for a transporter operatively linked with the transcription initiation region, and a termination sequence including a stop signal for RNA polymerase and a polyadenylation signal. It is understood that all of these regions should be capable of
- 20 operating in the biological cells to be transformed. The promoter region comprising the transcription initiation region, which preferably includes the RNA polymerase binding site, and the polyadenylation signal may be native to the biological cell to be transformed or may be derived from an alternative source, where the region is functional in the biological cell.
- 25 The transporters of this invention may be expressed in for example a plant cell under the control of a promoter that directs constitutive expression or regulated expression. Regulated expression comprises temporally or spatially regulated expression and any other form of inducible or repressible expression. Temporally means that the expression is induced at a certain time point, for instance, when a certain growth rate
- 30 of the plant cell culture is obtained (e.g. the promoter is induced only in the stationary phase or at a certain stage of development). Spatially means that the promoter is only active in specific organs, tissues, or cells (e.g. only in roots, leaves, epidermis, guard cells or the like. Other examples of regulated expression comprise promoters whose activity is induced or repressed by adding chemical or physical stimuli to the plant cell.

In a preferred embodiment the expression of the transporters is under control of environmental, hormonal, chemical, and/or developmental signals, also can be used for expression of transporters in plant cells, including promoters regulated by (1) heat, (2) light, (3) hormones, such as abscisic acid and methyl jasmonate (4) wounding or (5) chemicals such as salicylic acid, chitosans or metals. Indeed, it is well known that the expression of secondary metabolites can be boosted by the addition of for example specific chemicals, jasmonate and elicitors. The co-expression of transporters, in combination with a stimulation of secondary metabolite synthesis is beneficial for an optimal and enhanced production of secondary metabolites. Alternatively, the transporters can be placed under the control of a constitutive promoter. A constitutive promoter directs expression in a wide range of cells under a wide range of conditions. Examples of constitutive plant promoters useful for expressing heterologous polypeptides in plant cells include, but are not limited to, the cauliflower mosaic virus (CaMV) 35S promoter, which confers constitutive, high-level expression in most plant tissues including monocots; the nopaline synthase promoter and the octopine synthase promoter.

The expression cassette is usually provided in a DNA or RNA construct which is typically called an "expression vector" which is any genetic element, e.g., a plasmid, a chromosome, a virus, behaving either as an autonomous unit of polynucleotide replication within a cell (i.e. capable of replication under its own control) or being rendered capable of replication by insertion into a host cell chromosome, having attached to it another polynucleotide segment, so as to bring about the replication and/or expression of the attached segment. Suitable vectors include, but are not limited to, plasmids, bacteriophages, cosmids, plant viruses and artificial chromosomes. The expression cassette may be provided in a DNA construct which also has at least one replication system. In addition to the replication system, there will frequently be at least one marker present, which may be useful in one or more hosts, or different markers for individual hosts. The markers may a) code for protection against a biocide, such as antibiotics, toxins, heavy metals, certain sugars or the like; b) provide complementation, by imparting prototrophy to an auxotrophic host; or c) provide a visible phenotype through the production of a novel compound in the plant. Exemplary genes which may be employed include neomycin phosphotransferase (NPTII), hygromycin phosphotransferase (HPT), chloramphenicol acetyltransferase (CAT), nitrilase, and the gentamicin resistance gene. For plant host selection, non-

limiting examples of suitable markers are β -glucuronidase, providing indigo production, luciferase, providing visible light production, Green Fluorescent Protein and variants thereof, NPTII, providing kanamycin resistance or G418 resistance, HPT, providing hygromycin resistance, and the mutated *aroA* gene, providing glyphosate resistance.

5 The term "promoter activity" refers to the extent of transcription of a gene that is operably linked to the promoter whose promoter activity is being measured. The promoter activity may be measured directly by measuring the amount of RNA transcript produced, for example by Northern blot or indirectly by measuring the product coded for by the RNA transcript, such as when a reporter gene is linked to the
10 promoter. The term "operably linked" refers to linkage of a DNA segment to another DNA segment in such a way as to allow the segments to function in their intended manners. A DNA sequence encoding a gene product is operably linked to a regulatory sequence when it is ligated to the regulatory sequence, such as, for example a promoter, in a manner which allows modulation of transcription of the DNA sequence,
15 directly or indirectly. For example, a DNA sequence is operably linked to a promoter when it is ligated to the promoter downstream with respect to the transcription initiation site of the promoter and allows transcription elongation to proceed through the DNA sequence. A DNA for a signal sequence is operably linked to DNA coding for a polypeptide if it is expressed as a pre-protein that participates in the transport of the
20 polypeptide. Linkage of DNA sequences to regulatory sequences is typically accomplished by ligation at suitable restriction sites or adapters or linkers inserted in lieu thereof using restriction endonucleases known to one of skill in the art.

The term "heterologous DNA" or "heterologous RNA" refers to DNA or RNA that does not occur naturally as part of the genome or DNA or RNA sequence in which it is
25 present, or that is found in a cell or location in the genome or DNA or RNA sequence that differs from that which is found in nature. Heterologous DNA and RNA (in contrast to homologous DNA and RNA) are not endogenous to the cell into which it is introduced, but has been obtained from another cell or synthetically or recombinantly produced. An example is a human gene, encoding a human protein, operably linked to
30 a non-human promoter. Another example is a gene isolated from one plant species operably linked to a promoter isolated from another plant species. Generally, though not necessarily, such DNA encodes RNA and proteins that are not normally produced by the cell in which the DNA is transcribed or expressed. Similarly exogenous RNA encodes for proteins not normally expressed in the cell in which the exogenous RNA is

present. Heterologous DNA or RNA may also refer to as foreign DNA or RNA. Any DNA or RNA that one of skill in the art would recognize as heterologous or foreign to the cell in which it is expressed is herein encompassed by the term heterologous DNA or heterologous RNA. Examples of heterologous DNA include, but are not limited to, DNA that encodes proteins, polypeptides, receptors, reporter genes, transcriptional and translational regulatory sequences, selectable or traceable marker proteins, such as a protein that confers drug resistance, RNA including mRNA and antisense RNA and ribozymes.

Generally, two basic types of metabolites are synthesised in cells, i.e. those referred to as primary metabolites and those referred to as secondary metabolites. A primary metabolite is any intermediate in, or product of the primary metabolism in cells. The primary metabolism in cells is the sum of metabolic activities that are common to most, if not all, living cells and are necessary for basal growth and maintenance of the cells. Primary metabolism thus includes pathways for generally modifying and synthesising certain carbohydrates, proteins, fats and nucleic acids, with the compounds involved in the pathways being designated primary metabolites. In contrast hereto, secondary metabolites usually do not appear to participate directly in growth and development. They are a group of chemically very diverse products that often have a restricted taxonomic distribution. Secondary metabolites normally exist as members of closely related chemical families, usually of a molecular weight of less than 1500 Dalton, although some bacterial toxins are considerably longer. Secondary plant metabolites include e.g. alkaloid compounds (e.g. terpenoid indole alkaloids, tropane alkaloids, steroid alkaloids, polyhydroxy alkaloids), phenolic compounds (e.g. quinines, lignans and flavonoids), terpenoid compounds (e.g. monoterpenoids, iridoids, sesquiterpenoids, diterpenoids and triterpenoids). In addition, secondary metabolites include small molecules (i.e. having a molecular weight of less than 600), such as substituted heterocyclic compounds which may be monocyclic or polycyclic, fused or bridged. Many plant secondary metabolites have value as pharmaceuticals. Plant pharmaceuticals include e.g. taxol, digoxin, colchicines, codeine, morphine, quinine, shikonin, ajmalicine and vinblastine. The definition of "Alkaloids", of which more than 12.000 structures have been described already, includes all nitrogen-containing natural products which are not otherwise classified as peptides, non-protein amino acids, amines, cyanogenic glycosides, glucosinolates, cofactors, phytohormones or primary metabolites (such as purine and pyrimidine bases). The "calystegins" constitute a

unique subgroup of the tropane alkaloid class (Goldmann et al. (1990) *Phytochemistry*, 29, 2125). They are characterized by the absence of an N-methyl substituent and a high degree of hydroxylation. Trihydroxylated calystegins are summarized as the calystegin A-group, tetrahydroxylated calystegins as the B-group, and pentahydroxylated derivatives form the C-group. Calystegins represent a novel structural class of polyhydroxy alkaloids possessing potent glycosidase inhibitory properties next to longer known classes of the monocyclic pyrrolidones (e.g. dihydroxymethyl-dihydroxy pyrrolidine) pyrrolines and piperidines (e.g. deoxynojirimycin), and the bicyclic pyrrolizidines (e.g. australine) and indolizidines (e.g. swainsonine and castanospermine). Glycosidase inhibitors are potentially useful as antidiabetic, antiviral, antimetastatic, and immunomodulatory agents.

In another embodiment the invention provides a method for enhancing the production of at least one secondary metabolite in biological cells by transformation of said biological cells with an expression vector comprising an expression cassette further comprising a gene coding for an ABC transporter. Genes useful to be incorporated in an expression cassette for carrying out the present invention include those coding for ATP-binding cassette (ABC) transporters. Genes encoding ABC-transporters can be of any species or origin, including microorganisms, plant and animal (Higgins (1992) *Ann. Rev. Cell Biol.* 8, 67), but are preferably of plant or fungal origin. The ATP-binding cassette (ABC) transporters, also called the "traffic ATPases", comprise a superfamily of membrane proteins that mediate transport and channel functions in prokaryotes and eukaryotes (Higgins, C. F. (1992) *Annu. Rev. Cell Biol.* 8:67-113; Theodoulou F. (2000) *Biochimica et Biophysica Acta* 1465, 79). Typically, an ABC transporter contains two copies each of two structural units: a highly hydrophobic transmembrane domain (TMD), and a peripherally located ATP binding domain or nucleotide binding fold (NBF), which together are often necessary and sufficient to mediate transport. The TMD domains form the pathway via which the substrate crosses the membrane, and in some cases, have been shown to contribute to the substrate specificity. The NBFs are oriented towards the cytoplasmic side of the membrane and couple ATP hydrolysis to transport. Within the NBF is a conserved region of approximately 200 amino acids, consisting of the Walker A and B boxes separated by the ABC signature motif. It is this signature motif which distinguishes ABC transporters from other NTP binding proteins, such as the kinases, which also contain the Walker sequences. Sequence homology

over the whole gene can be negligible between different ABC transporters, but in the conserved areas of the NBF it is typically 30-40% between family members, and this has proved useful in the isolation of ABC genes by approaches such as PCR and hybridisation with degenerate nucleotides (Dudler R. et al (1998) Methods Enzymol. 292, 162). A great variety of specific substrates is transported by members of this family of transport proteins, including drugs, anorganic ions, amino acids, proteins, sugars, and polysaccharides. Eukaryotic ABC proteins include: P-glycoproteins, also known as multidrug resistance (MDR) proteins, which are associated with resistance to a wide range of hydrophobic drugs (MDR1; Gottesman, M. M. & Pastan, I. (1993) Annu. Rev. Biochem. 62:385-427) or with phosphatidylcholine transport (MDR2; Ruetz, S. & Gros, P. (1994) Cell 77:1071-1081); CFTR, the cystic fibrosis transmembrane conductance regulator (Welsh, M. J. & Smith, A. E. (1993) Cell 73:1251-1254); TAP proteins, the transporters associated with antigen processing in mammalian cells (Androlewicz, M. J. et al. (1994) Proc. Natl. Acad. Sci. USA 91:12716-12720); cMOAT/cMRP1, which is associated with transport of glutathione, glucuronide, and sulfate conjugates across the canalicular membrane (Buchler, M. et al. (1996) J. Biol. Chem. 271:15091-15098); and STE6, which exports the α -factor mating pheromone of *S. cerevisiae* (Michaelis, S. (1993) Semin. Cell Biol. 4:17-27) and PDR5, the pleiotropic drug resistance protein of yeast. Prokaryotic ABC proteins include periplasmic nutrient permeases, such as those responsible for uptake of maltose (MalFGK) and histidine (HisMPQ) in gram-negative bacteria, and toxin exporters such as those required for export of hemolysin (HlyB) and colicin (ColV) from *E. coli*. Sequence comparisons between MRP1 and other ABC transporters reveal two major subgroups among these proteins (Szczypka et al. (1994) J. Biol. Chem. 269, 22853). One subgroup comprises MRP1, the *Saccharomyces cerevisiae* cadmium factor (YCF1) gene, the *Leishmania* P-glycoprotein-related molecule (Lei/PgpA) and the CFTRs. The other subgroup comprises the multiple drug resistance proteins (MDRs), MHC transporters and STE6. Homologues of ABC-transporters have been identified in plant species. In *Arabidopsis thaliana*, the glutathione-conjugate transporter (MRP) is located in the vacuolar membrane and is responsible for sequestration of xenobiotics in the central vacuole. An MDR-like gene (atpgp1) has also been identified in *A. thaliana*, which encodes a putative P-glycoprotein homolog. This atpgp1 gene was found to share significant sequence homology and structural organization with human MDR genes. Other MDR homologues have been found in potato and barley. Genes encoding ABC-transporters

of the present invention which may be operably linked with a promoter for expression in a plant species may be derived from a chromosomal gene, cDNA, a synthetic gene, or combinations thereof.

In another embodiment of the invention DNA sequences encoding ABC-transporters are used to enhance the production of at least one secondary metabolite in plant cells comprising the transformation of said plant cells with an expression vector comprising an expression cassette further comprising a gene coding for an ABC-transporter.

By the term "enhanced production" it is meant that the level of one or more metabolites may be enhanced by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or at least 100% relative to the untransformed plant cell which was used to transform with an expression vector comprising an expression cassette further comprising a gene coding for a transporter or an ABC-transporter. An enhanced production of a secondary metabolite can result in a detection of a higher level of secondary metabolites in the extracellular medium of the plant cell culture. Alternatively, a higher level of secondary metabolites can be detected inside the plant cells, for example in the vacuole.

The present invention can be practiced with any plant variety for which cells of the plant can be transformed with an expression cassette of the current invention and for which transformed cells can be cultured *in vitro*. Suspension culture, callus culture, hairy root culture, shoot culture or other conventional plant cell culture methods may be used (as described in: *Drugs of Natural Origin*, G. Samuelsson, 1999, ISBN 9186274813).

By "plant cells" it is understood any cell which is derived from a plant and can be subsequently propagated as callus, plant cells in suspension, organized tissue and organs (e.g. hairy roots).

Tissue cultures derived from the plant tissue of interest can be established. Methods for establishing and maintaining plant tissue cultures are well known in the art (see, e.g. Trigiano R.N. and Gray D.J. (1999), "Plant Tissue Culture Concepts and Laboratory Exercises", ISBN: 0-8493-2029-1; Herman E.B. (2000), "Regeneration and Micropropagation: Techniques, Systems and Media 1997-1999", Agricell Report).

Typically, the plant material is surface-sterilized prior to introducing it to the culture medium. Any conventional sterilization technique, such as chlorinated bleach treatment can be used. In addition, antimicrobial agents may be included in the growth medium. Under appropriate conditions plant tissue cells form callus tissue, which may

be grown either as solid tissue on solidified medium or as a cell suspension in a liquid medium.

A number of suitable culture media for callus induction and subsequent growth on aqueous or solidified media are known. Exemplary media include standard growth media, many of which are commercially available (e.g., Sigma Chemical Co., St. Louis, Mo.). Examples include Schenk-Hildebrandt (SH) medium, Linsmaier-Skoog (LS) medium, Murashige and Skoog (MS) medium, Gamborg's B5 medium, Nitsch & Nitsch medium, White's medium, and other variations and supplements well known to those of skill in the art (see, e.g., *Plant Cell Culture*, Dixon, ed. IRL Press, Ltd. Oxford (1985) and George et al., *Plant Culture Media*, Vol 1, Formulations and Uses Exegetics Ltd. Wilts, UK, (1987)). For the growth of conifer cells, particularly suitable media include 1/2 MS, 1/2 L.P., DCR, Woody Plant Medium (WPM), Gamborg's B5 and its modifications, DV (Durzan and Ventimiglia, *In Vitro Cell Dev. Biol.* 30:219-227 (1994)), SH, and White's medium.

When secondary metabolites are produced in plant cell culture systems they usually have to be extracted and purified from the isolated plant cell mass which is an expensive process. It is known that plants can be made by means of genetic manipulation to store proteins in seed endosperm, from where they can be more easily extracted. It has also been described that some plant cells can secrete secondary metabolites can be secreted and that said secretion can be enhanced by for example the addition of elicitors (Kneer et al. (1999) *J. Exp. Bot.* 50, 1553) or by the addition of specific chemicals (Lee et al. (1998) *Phytochemistry* 49, 2342). It has however never been described that the secretion of secondary metabolites by plant cells can be induced or enhanced by the transformation of at least one specific gene into a plant cell. The present invention provides a solution for this problem by transformation of plant cells, producing secondary metabolites, with an expression cassette comprising a gene encoding an ABC-transporter. Therefore, in another embodiment of the invention a DNA sequence encoding an ABC-transporter can be used to induce or enhance the secretion of at least one secondary metabolite produced in plant cell cultures comprising transforming said plant cells that are producing secondary metabolites, with an expression vector comprising an expression cassette further comprising a gene coding for an ABC-transporter, and selecting transformed plant cells with an induced or enhanced secretion of at least one secondary metabolite. Such transformed plant cells can be subsequently propagated using methods described herein before.

An "enhanced secretion of at least one secondary metabolite" means that there exists already a detectable secretion of the secondary metabolite(s) in the extracellular medium of the plant cell culture and that an increase of the secondary metabolite(s) can be measured by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more than 90% compared to basal secretion by the untransformed plant cell culture. An
5 'enhanced secretion' does not necessarily mean that there is a higher production, it can also mean that there is exists the same level of production but that the secretion is enhanced. An "induced secretion of at least one secondary metabolite" means that there is no detectable secretion of the secondary metabolite(s) in the extracellular
10 medium of the untransformed plant cell culture but that the detection becomes possible upon carrying out the transformation according to the invention.

Generally secondary metabolites can be measured, intracellularly or in the extracellular space, by methods known in the art. Such methods comprise analysis by thin-layer chromatography, high pressure liquid chromatography, capillary
15 chromatography, (gas chromatographic) mass spectrometric detection, radioimmuno-assay (RIA) and enzyme immuno-assay (ELISA).

In order to make clear what is meant by the word "secretion" in the current invention one has to make a clear distinction between the secretion of proteins which is mediated by an amino-terminal signal peptide and the secretion of secondary
20 metabolites which is independent of an amino-terminal leader sequence. As the term is used herein, secretion means secretion of a secondary metabolite across the plasma membrane or secretion across both the plasma membrane and the cell wall of a plant cell. It should be noted that, in the scientific literature the term "secretion" often is used to indicate secretion into the apoplastic space, i.e., secretion across the plasma
25 membrane but not across the cell wall.

In one aspect of the invention there is no secretion of (a) secondary metabolite(s) into the growth medium. Then, the secretion can be induced by several possibilities: (1) by the transformation of the plant cell with a heterologous gene encoding an ABC-transporter or (2) by the overexpression of a homologous ABC-transporter which
30 expressing is rate-limiting in the plant cell or (3) by the relocalisation of a homologous or heterologous ABC-transporter from a vacuolar localisation towards a membrane localisation. In plants, proteins destined for the vacuole are sorted away from proteins destined for secretion at the trans-Golgi network, a process that requires the presence of positive sorting signals on the vacuolar proteins. Three types of sorting signals have

been described for soluble vacuolar proteins in plants (Matsuoka and Neuhaus (1999) J. Exp. Botany 50, 165). Some proteins contain a cleavable amino-terminal propeptide that functions as a sorting signal while others contain a cleavable carboxy-terminal propeptide. Finally, a minor amount of plant proteins contains an internal vacuolar targeting determinant. According to the invention a homologous or heterologous ABC-transporter that is normally localized in the vacuolar membrane can be engineered by clipping off its vacuolar localisation signal (carboxy-terminal or amino-terminal propeptide) or by deleting its internal vacuolar targeting determinant. If necessary a heterologous or homologous amino-terminal leader sequence is spliced to the gene encoding the homologous or heterologous ABC-transporter in order to provide entry into the secretion system. As a result said engineered ABC-transporter is not directed anymore in the secretion pathway towards its normal vacuolar localisation but is deviated towards the extracellular space. However, due to the hydrophobic transmembrane signal present in ABC-transporters, the ABC-transporter is not secreted into the extracellular medium but remains sequestered into the plasmamembrane of the plant cell. We show in the present invention that the novel intracellular localisation of the ABC-transporter (from the vacuole to the plasma membrane) results in a secretion of the produced secondary metabolites into the medium of the plant cell culture.

In another aspect of the invention there is already an existing but a low level of secretion of (a) secondary metabolite(s) by the plant cell and then the secretion can be enhanced by (1) by the transformation of the plant cell with a heterologous gene encoding an ABC-transporter or (2) by the overexpression of a homologous ABC-transporter which expressing is rate-limiting in the plant cell or (3) by the relocation of a homologous or heterologous ABC-transporter from a normal vacuolar localisation towards a membrane localisation.

In yet another aspect of the invention an intermediary product of the secondary metabolite, which causes negative feedback inhibition on an enzymatic reaction step involved in the biosynthesis of said secondary metabolite, can be secreted by (1) by the transformation of the plant cell with a heterologous gene encoding an ABC-transporter or (2) by the overexpression of a homologous ABC-transporter which expressing is rate-limiting in the plant cell or (3) by the relocation of a homologous or heterologous ABC-transporter from a vacuolar localisation towards a membrane localisation. The secretion of said intermediary product or an amount produced thereof

reduces the negative feedback inhibition and consequently enhances the production of the secondary metabolite in the plant cell. The enhanced production of said secondary metabolite can be made secreted by the plant cell by the transformation of the already transformed plant cell, with a second expression cassette comprising a gene encoding an ABC transporter, according to the method described above. In this case of secretion, the directed secondary metabolites can be easily isolated from the surrounding medium since they are directed into the extracellular space. Consequently, the breaking up of the cells that is necessary in the case of intracellular production can be omitted.

In another embodiment of the invention the production of secondary metabolites can be enhanced by stimulating the transport of secondary metabolites into the vacuole. In plants, the targeting of proteins and compounds into the vacuole is of particular interest (especially from the point of view of application) because the vacuole is the largest storage compartment in the cell for reserve substances, detoxification products and defence substances. The most important storage takes place in vacuoles in plant organs such as tubers, bulbs, roots and stems. Similar considerations also apply to substances that can be used in the control of pests or diseases, especially when those substances prove to be toxic to the plant itself. Indeed, in certain cases the vacuole also serves as a detoxification organ by, for example, storing the detoxification products synthesised by the plant. According to the present invention secondary metabolites can also be made secreted into the vacuole (1) by the transformation of a plant cell with a heterologous gene encoding an ABC-transporter or (2) by the overexpression of a homologous ABC-transporter which expressing is rate-limiting in the plant cell or (3) by the relocalisation of a homologous or heterologous ABC-transporter from a normally localised plasmamembrane localisation towards a vacuolar localisation. To perform said relocalisation it is necessary to modify the gene encoding an ABC-transporter by genetically fusing it to an amino-terminal or carboxy-terminal vacuolar localisation signal or by the genetic modification through the introduction of an existing internal vacuolar localisation signal. US patent 6,054,637 provides detailed information of genetic modification of genes through the addition or clipping off plant vacuolar localisation signals. We observe that the secretion or targeting of the produced secondary metabolites into the vacuole reduces the toxicity to the plant cell. In yet another embodiment of the invention an intermediary product of the secondary metabolite, which causes negative feedback inhibition on an enzymatic reaction step

involved in the biosynthesis of said secondary metabolite, can be made sequestered into the vacuole by (1) the transformation of the plant cell with a heterologous gene encoding an ABC-transporter or by (2) the overexpression of a homologous ABC-transporter which expressing is rate-limiting in the plant cell or (3) by the relocalisation of a homologous or heterologous ABC-transporter from a normal membrane localisation towards a vacuolar localisation. The import of said intermediary product, or an amount produced thereof, into the vacuole reduces the negative feedback inhibition of the enzymatic reaction which occurs outside the vacuole and consequently enhances the production of the secondary metabolite in the plant cell.

- 10 In another embodiment the current invention can be combined with other known methods to enhance the production and/or the secretion of secondary metabolites in plant cell cultures such as (1) by improvement of the plant cell culture conditions, (2) by the transformation of the plant cells with a transcription factor capable of upregulating genes involved in the pathway of secondary metabolite formation, (3) by the addition of specific elicitors to the plant cell culture, and 4) by the induction of organogenesis.

In another embodiment of the invention DNA sequences encoding ABC-transporters are used to enhance the production of at least one secondary metabolite in plants comprising the transformation of said plants with an expression vector comprising an expression cassette further comprising a gene coding for an ABC-transporter.

- 20 By the term "to enhance the production" it is meant that the level of one or more metabolites may be enhanced by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or at least 100% relative to the untransformed plant which was used to transform with an expression vector comprising an expression cassette further comprising a gene coding for a transporter or an ABC-transporter. An enhanced production of a secondary metabolite can result in a detection of a higher level of secondary metabolites in the plant, for example in the vacuole. In another embodiment the enhanced production of at least one secondary metabolite leads to an enhanced secretion. In yet another embodiment the same production of at least one secondary metabolite occurs in the transformed plant but an enhanced secretion of at least one secondary metabolite occurs by said transformed plant. Secondary metabolites can for example be efficiently produced by continuous secretion from the roots of hydroponically grown plants. This process of secretion is also been termed 'rhizosecretion'.

The term "plant" as used herein refers to vascular plants (e.g. gymnosperms and angiosperms). The method comprises transforming a plant cell with an expression cassette of the present invention and regenerating such plant cell into a transgenic plant. Such plants can be propagated vegetatively or reproductively. The transforming

5 step may be carried out by any suitable means, including by *Agrobacterium*-mediated transformation and non-*Agrobacterium*-mediated transformation, as discussed in detail below. Plants can be regenerated from the transformed cell (or cells) by techniques known to those skilled in the art. Where chimeric plants are produced by the process, plants in which all cells are transformed may be regenerated from chimeric plants

10 having transformed germ cells, as is known in the art. Methods that can be used to transform plant cells or tissue with expression vectors of the present invention include both *Agrobacterium* and non-*Agrobacterium* vectors. *Agrobacterium*-mediated gene transfer exploits the natural ability of *Agrobacterium tumefaciens* to transfer DNA into plant chromosomes and is described in detail in Gheysen, G., Angenon, G. and Van

15 Montagu, M. 1998. *Agrobacterium*-mediated plant transformation: a scientifically intriguing story with significant applications. In K. Lindsey (Ed.), Transgenic Plant Research. Harwood Academic Publishers, Amsterdam, pp. 1-33 and in Stafford, H.A. (2000) Botanical Review 66: 99-118. A second group of transformation methods is the non-*Agrobacterium* mediated transformation and these methods are known as direct

20 gene transfer methods. An overview is brought by Barcelo, P. and Lazzeri, P.A. (1998) Direct gene transfer: chemical, electrical and physical methods. In K. Lindsey (Ed.), Transgenic Plant Research, Harwood Academic Publishers, Amsterdam, pp.35-55. Hairy root cultures can be obtained by transformation with virulent strains of *Agrobacterium rhizogenes*, and they can produce high contents of secondary

25 metabolites characteristic to the mother plant. Protocols used for establishing of hairy root cultures vary, as well as the susceptibility of plant species to infection by *Agrobacterium* (Toivunen L. (1993) Biotechnol. Prog. 9, 12; Vanhala L. et al. (1995) Plant Cell Rep. 14, 236). It is known that the *Agrobacterium* strain used for transformation has a great influence on root morphology and the degree of secondary

30 metabolite accumulation in hairy root cultures. It is possible that by systematic clone selection e.g. via protoplasts, to find high yielding, stable, and from single cell derived-hairy root clones. This is possible because the hairy root cultures possess a great somaclonal variation. Another possibility of transformation is the use of viral vectors (Turpen TH (1999) *Philos Trans R Soc Lond B Biol Sci* 354(1383): 665-73).

Any plant tissue or plant cells capable of subsequent clonal propagation, whether by organogenesis or embryogenesis, may be transformed with an expression vector of the present invention. The term 'organogenesis' means a process by which shoots and roots are developed sequentially from meristematic centers; the term

5 'embryogenesis' means a process by which shoots and roots develop together in a concerted fashion (not sequentially), whether from somatic cells or gametes. The particular tissue chosen will vary depending on the clonal propagation systems available for, and best suited to, the particular species being transformed. Exemplary tissue targets include protoplasts, leaf disks, pollen, embryos, cotyledons, hypocotyls,

10 megagametophytes, callus tissue, existing meristematic tissue (e.g. apical meristems, axillary buds, and root meristems), and induced meristem tissue (e.g., cotyledon meristem and hypocotyls meristem).

These plants may include, but not limited to, plants or plant cells of agronomically important crops, such as tomato, tobacco, diverse herbs such as oregano, basilicum

15 and mint. It may also be applied to plants that produce valuable compounds, e.g. useful as for instance pharmaceuticals, as ajmalicine, vinblastine, vincristine, ajmaline, rserpine, rescinnamine, camptothecine, ellipticine, quinine, and quinidien, taxol, morphine, scopolamine, atropine, cocaine, sanguinarine, codeine, genistein, daidzein, digoxin, colchicines, calystegins or as food additives such as anthocyanins, vanillin;

20 including but not limited to the classes of compounds mentioned above. Examples of such plants include, but not limited to, *Papaver spp.*, *Rauvolfia spp.*, *Taxus spp.*, *Cinchona spp.*, *Eschscholtzia californica*, *Camptotheca acuminata*, *Hyoscyamus spp.*, *Berberis spp.*, *Coptis spp.*, *Datura spp.*, *Atropa spp.*, *Thalictrum spp.*, *Peganum spp.*

25 In another embodiment the invention provides an isolated polypeptide selected from the groups consisting of (a) an isolated polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO: 1; (b) an isolated polypeptide comprising a polypeptide sequence having a least 83 % identity to the polypeptide sequence of SEQ ID NO: 2; (c) fragments and variants of such polypeptides in (a) to (b) that induce or

30 enhance the production or the secretion of at least one secondary metabolite in plants or plant cells.

In another embodiment the invention provides an isolated polynucleotide selected from the groups consisting of (a) an isolated polynucleotide comprising a polynucleotide

sequence of SEQ ID NO: 1; (b) an isolated polynucleotide comprising a polynucleotide sequence having at least 91% identity to SEQ ID NO: 1; (c) fragments and variants of such polynucleotides in (a) to (b) that induce or enhance the production or the secretion of at least one secondary metabolite in plants or plant cells.

- 5 As used herein, the words "polynucleotide" may be interpreted to mean the DNA and cDNA sequence as detailed by Yoshikai et al. (1990) *Gene* 87:257, with or without a promoter DNA sequence as described by Salbaum et al. (1988) *EMBO J.* 7(9):2807. As used herein, "fragment" refers to a polypeptide or polynucleotide of at least about 9 amino acids or 27 base pairs, typically 50 to 75, or more amino acids or base pairs, wherein the polypeptide contains an amino acid core sequence. If desired, the fragment may be fused at either terminus to additional amino acids or base pairs, which may number from 1 to 20, typically 50 to 100, but up to 250 to 500 or more. A "functional fragment" means a polypeptide fragment possessing the biological property of that induce or enhance the production or the secretion of at least one secondary metabolite in plants or plant cells. The terms 'identical' or percent 'identity' in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e. 70% identity over a specified region), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using sequence comparison algorithms or by manual alignment and visual inspection. Preferably, the identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides or even more in length. Examples of useful algorithms are PILEUP (Higgins & Sharp, *CABIOS* 5:151 (1989), BLAST and BLAST 2.0 (Altschul et al. *J. Mol. Biol.* 215: 403 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>).

Examples

- 30 The recombinant DNA and molecular cloning techniques applied in the below examples are all standard methods well known in the art and are e.g. described by Sambrook et al. (1989) *Molecular cloning: A laboratory manual*, second edition, Cold Spring Harbor Laboratory Press. Methods for yeast culture and manipulation applied in the below examples are all standard methods well known in the art and are described

e.g. in Guthrie and Fink (1991) Guide to yeast genetics and molecular biology, academic Press, Inc., New York. Methods for tobacco cell culture and manipulation applied in the below examples are methods described in or derived from methods described in Nagata et al. (1992) Int. Rev. Cytol. 132, 1.

5

EXAMPLE 1: Identification of yeast multidrug resistance transporters specific for tropane (Tas) and nicotine-type alkaloids (NAs)

In the yeast *Saccharomyces cerevisiae*, a complex pleiotropic drug resistance (PDR) network of genes involved in multidrug resistance is composed of the transcriptional regulators Pdr1p and Pdr3p, which activate expression of the ATP-binding cassette (ABC) transporter-encoding genes *PDR5*, *SNQ2*, *YOR1*, as well as other not yet identified genes. To assess yeast sensitivity towards tropane alkaloids (Tas) and nicotine alkaloids (Nas) and identify yeast ABC transporters with specificity for TAs and NAs, we have screened isogenic yeast strains deleted of the ABC transporters *YOR1*, *SNQ2*, *PDR5*, *PDR10*, *PDR11* or *YCF1* for tolerance to the toxic compounds hyoscyamine, scopolamine and nicotine. The isogenic yeast strains derived from the US50-18C genotype were constructed and described in Decottignies et al. (*J. Biol. Chem.* (1998) 273, 12612). The yeast strains derived from the BY4741 genotype are obtained from the EUROSCARF collection (Frankfurt, Germany). All strains are listed in Table 1.

Table 1. Yeast strains used	
Strain	Genotype
US50-18C	<i>Mata pdr1-3 ura3 his1</i>
AD1	US50-18C <i>yor1::hisG</i>
AD2	US50-18C <i>snq2::hisG</i>
AD3	US50-18C <i>pdr5::hisG</i>
AD4	US50-18C <i>pdr10::hisG</i>
AD5	US50-18C <i>pdr11::hisG</i>
BY4741	<i>Mata his3Δ1 leu2Δ0 met15Δ0 ura3Δ0</i>
Y02409	BY4741 <i>pdr5::kanMX4</i>
Y03951	BY4741 <i>snq2::kanMX4</i>
Y04069	BY4741 <i>ycf1::kanMX4</i>
Y05933	BY4741 <i>yor1::kanMX4</i>

Alkaloid tolerance was assessed by controlling growth performance on rich medium (YPD) that contained different concentrations of TAs or NAs. To this end the different strains were grown to saturation (48h) in liquid YPD. Cultures were diluted 10-, 100- and 1000-fold, and volumes of about 3 µl were dropped with a stainless steel replicator on YPD plates containing 2% Bacto Agar with the toxic compounds. Rich medium contains 1% yeast extract, 2% Bacto Peptone and 2% glucose. Filter-sterilized water solutions of hyoscyamine, scopolamine and nicotine were added after autoclaving. Growth was evaluated after two days incubation at 28°C. We observed that wild type yeast (i.e. not deleted for one of the ABC transporters) can tolerate hyoscyamine, scopolamine and nicotine to levels of 50 mM, 100 mM, and 15 mM respectively. Gradually increasing alkaloid levels in the medium caused growth retardation and was finally lethal. All isogenic strains except the *pdr5* mutant strain showed identical alkaloid sensitivity. The above-mentioned alkaloid concentrations were lethal for the strain deleted for the *PDR5* gene. This indicates that Pdr5p shows substrate specificity for TAs and NAs and is the only known ABC transporter involved in TA or NA transport in yeast cells. Previously other plant secondary metabolites such as indole alkaloids (e.g. vinblastine and vincristine), taxol and flavonoids were also shown to be substrates for Pdr5p mediated multidrug transport (Kolaczowski et al. (1996) J. Biol. Chem. 271, 31543 and Kolaczowski et al. (1998) Microb. Drug Resist. 4, 143).

EXAMPLE 2: Assessment of toxicity of TAs and NAs to tobacco BY-2 suspension cultured cells

Suspension cultured tobacco cells, *Nicotiana tabacum* L. cv Bright Yellow 2 were grown in the dark at 26°C on a rotary shaker (130 rpm) in MSST, a modified Murashige-Skoog basal medium supplemented with 1.5 mM KH₂PO₄, 3 µM thiamine, 0.55 mM inositol, 87 mM sucrose and 1 µM 2,4D. Cells are subcultured every 7 days by transferring 0.5 ml into 50 ml of fresh medium in 250-ml flasks.

Toxicity of TAs and NAs to tobacco BY-2 cells was assessed in two ways. In the first method growth performance on MSST medium containing different concentrations of TAs or NAs was controlled. To this end a fresh BY-2 cell culture was started and after 3 days culture volumes of about 300 µl were dropped on MSST plates containing 0.65% Bacto Agar and the toxic alkaloids. Filter-sterilised water solutions of hyoscyamine and nicotine were added after autoclaving. Growth was evaluated after

15 days incubation at 26°C. Wildtype BY-2 cells (i.e. not transgenic) can tolerate hyoscyamine and nicotine without severe growth problems to levels of 30 mM and 3 mM respectively. Gradually increasing alkaloid levels in the medium caused growth retardation and finally was lethal. In the second method toxicity was evaluated by measuring cell death after incubation in the presence of increasing levels of alkaloids. Cell death was scored by the Evans blue method (Turner and Novacky (1974) *Phytopathol.* 64, 885). To this end a fresh BY-2 cell culture was started and after 3 days 5 ml of this culture was transferred to one well of a 6-well plate (Falcon 353046). 1 ml of fresh MSST was added and the desired toxic compound in a volume of 650 µl in 0.1M potassium phosphate buffer at pH 5.8. Cells were then further incubated on the rotary shaker and 1-ml samples were taken after 0, 6 and 24 hours. We spinned the cells down at 6000 rpm for 3 minutes, removed the supernatant, added 1 ml of 0.1% Evans blue in MSST medium and incubated for 15 minutes at room temperature on a rotary wheel. Afterwards we spinned the cells down again and washed 5 times with fresh MSST medium till all the blue color was gone from the supernatant. Dye bound to dead cells was solubilised by incubation in 1 ml of 50% methanol, 1% SDS for 30 minutes at 50°C. We spinned the cells down again (now at 14000 rpm for three minutes) and quantified cell death by measuring OD₆₀₀ of the supernatant. Cell death is expressed as fold increase in Evans blue staining compared to the control cells. In this assay tobacco BY-2 cells are found sensitive to all the compounds tested. Hyoscyamine and nicotine cause the death of all suspension cultured tobacco cells within 24 hours of incubation at levels of 50 mM and 20 mM respectively. This indicates that the metabolites that plants produce inside the cells can be toxic for themselves and also that this toxicity can result in slow growth of plant cells producing secondary metabolites. Furthermore these results provided us with useful assay systems for evaluating the activity of ABC transporters from different organisms such as yeast, plants and animals in tobacco cell suspension cultures.

EXAMPLE 3: Expression of *PDR5* in tobacco BY-2 suspension cultured cells

30 3.1 Cloning of *PDR5*

The *PDR5* gene was cloned by the PCR method with the *PfuI* polymerase. To this end oligonucleotides were designed with 5'-terminal *attB* sequences that amplify the entire open reading frame of the *PDR5* gene (4536 nt) as a PCR product that is an efficient substrate for recombination with the Gateway™ system (InVitroGen). Gateway

(Invitrogen) technology provides an alternative rapid method for cloning a sequence into a multiple expression system. The advantage of the Gateway cloning is that fragments present as Entry clones can be subcloned into different Destination vectors in a short time. This technology was used to construct a set of versatile vectors for

5 Agrobacterium -based plant transformation. Our intention was to develop vectors for wide range plant gene analysis. The Gateway-compatible binary vector pPZP200 is the backbone of our constructs (Hajdukiewicz et al. *Plant Molecular Biology* 25, 989-994, 1994). This binary vector is relatively small in size, contains two origins of replication in *E. coli* or in *Agrobacterium* and possesses streptomycin and/or spectinomycin

10 for plasmid selection. Three plant selectable marker genes; kanamycin, hygromycin and bar (most frequently used markers in plant transformation) have been used for all constructs. All selectable markers are in a cassette containing nos (nopaline synthase) promoter and nos terminator. These genes were cloned toward the left border of the T-DNA. For construction of all Gateway clones we have used the rA conversion

15 cassette.

The oligonucleotides used for *PDR5* gene cloning, are 5'-AAAAGCAGGCTACCATGCCCCGAGGCCAAGCTTAACAATA-3' as the forward primer and 5'-AGAAAGCTGGGTCCATCTTGTAAGTTTCTTTCTTAACC-3' as the reverse

20 primer, respectively. As a template genomic DNA prepared from the yeast strains US50-18C or W303 was used. First the PCR fragments were introduced in the Donor Vector pDONR201 (InvitroGen) via the BP reaction to generate the Entry Clone. Then the *PDR5* gene was transferred to the Destination Vector pK7WGD2 (Fig. 1) via the LR reaction, where the gene is under control of the CaMV 35S promoter. The T-DNA

25 of the pK7WGD2 binary vector also bears the kanamycin resistance gene (NPTII) under the control of the pnos promoter as selectable marker for plant transformation and the gene encoding the green fluorescent protein (GFP) under the control of the proID promoter for visual selection of transgenic plant cell lines. The resulting binary plasmids were designated pK7WGD2-ScPDR5-US50 or pK7WGD2-ScPDR5-W303

30 depending on the yeast genotype from which the gene is isolated. Also the GUS gene was introduced in the pK7WGD2 vector and the resulting binary vector pK7WGD2-GUS served as a control for the experiments described in the examples below.

3.2 Transformation of tobacco BY-2 suspension cultured cells

Plant cell transformations were carried out by applying the ternary vector system (van

35 der Fits et al. (2000) *Plant Mol. Biol.* 43, 495). The plasmid pBBR1MCS-5.virGN54D is

used as a ternary vector. The binary plasmid was introduced into *Agrobacterium tumefaciens* strain LBA4404 already bearing the ternary plasmid by electro-transformation.

Agrobacterium tumefaciens strains were grown for three days at 28°C on solid LC medium containing 20 µg/ml rifampicin, 40 µg/ml geneticin, 100 µg/ml spectinomycin and 300 µg/ml streptomycin. LC medium contains 1% Bacto Trypton, 0.5% Bacto yeast extract and 0.8% NaCl. From these bacteria a 5-ml liquid culture was grown in LC medium for 48 hours. *N. tabacum* BY-2 cells were grown in MSST medium as described in example 2. For transformation 3 days old cell cultures were used. For cocultivation 4 ml of BY-2 cells was transferred to the corner of a petridish (Ø 80 mm) and 300 µl of the *A. tumefaciens* culture was added. Dishes were taped with respiratory tape and incubated for 3 days at 26°C in the dark. After 3 days the cocultivation mixture was transferred into 20 ml of fresh MSST medium 50 µg/ml kanamycin-B, 500µg/ml carbenicilin and 250 µg/ml vancomycin in 100-ml flasks and further incubated as described in example 2. After one week 4 ml of this cell suspension culture was subcultured in 40 ml of fresh MSST medium with 10 µg/ml of the kanamycin analogue G-418 (geneticin), 500µg/ml carbenicilin and 250 µg/ml vancomycin and grown further till it reached maximal density (similar to stationary, 1-week-old culture) which took two to three weeks, depending on the efficiency of the transformation event. After two additional 1 ml transfer cycles in medium containing 50 µg/ml kanamycin-B, 500µg/ml carbenicilin and 250 µg/ml vancomycin cells were further propagated in an antibiotic-free MSST medium as described in example 2. Elimination of agrobacteria was verified and efficient transgene expression was scored *in vivo* by observing GFP fluorescence with a fluorescence microscope equipped with HQ-GFP band-pass filters for an excitation at 470 and emission at 525 nm.

3.3 Effect of heterologous PDR5 expression in BY-2 suspension cultured cells on alkaloid tolerance

In recombinant BY-2 cells transformed with the PDR5 expression cassettes (from both yeast genotypes), correct PDR5 expression is tested by northern blot analysis using a *PDR5* specific DNA probe and by western blot analysis using a rabbit polyclonal anti-Pdr5p antibody (Decottignies et al. (1999) J. Biol. Chem. 274, 37139). In both lines *PDR5* is efficiently expressed both on the RNA and protein level. Fractionation also shows that the Pdr5 protein is correctly targeted to the plasma membrane. Tolerance of the transformed BY-2 suspension cultures to hyoscyamine and nicotine was

assessed by the two assays described in example 2. As can be deduced from the growth performance assay, BY-2 cell lines expressing the different yeast Pdr5 transporters displayed to varying extents an increased tolerance to both alkaloids as compared to the control GUS-expressing lines. Lines expressing the PDR5 transporter from yeast genotype W303 showed the highest alkaloid tolerance, in particular towards hyoscyamine. In the cell death experiment hyoscyamine was added to a final concentration of 30 mM. Transgene BY-2 cells expressing the Pdr5p from yeast strain W303 again showed the highest tolerance to this tropane alkaloid (Fig. 2). Fold increase in cell death lowered with ca. 35% in the W303 lines whereas US50 lines had a 15% decrease in hyoscyamine induced cell death.

3.4 Effect of heterologous PDR5 expression in BY-2 suspension cultured cells on nicotinic alkaloid production

For the analysis of nicotinic alkaloid accumulation 6-days old recombinant BY-2 cell cultures (BY-2 transformed with pK7WGD2-ScPDR5-US50 or pK7WGD2-ScPDR5-W303 or pK7WGD2-GUS) were washed and diluted ten-fold with fresh hormone free MSST medium. After a recuperation period of 12 hours, the cultures were treated with methyl jasmonate (MeJA). MeJA was dissolved in dimethyl sulfoxide (DMSO) and added to the culture medium at a final concentration of 50 μ M. As a control, cells treated with an equivalent amount of DMSO were included. For alkaloid analysis, three replicate shake flasks with a volume of 20 ml were processed. After vacuum-filtering through Miracloth, cells and medium were separated from each other for intracellular and extracellular alkaloid analysis respectively. The filtered cell mass was transferred to a test tube, frozen and lyophilized (50 mbar, approx. 48 hours). Lyophilised cell samples were extracted for GC-MS analysis by a modified method described by Furuya et al. (1971, Phytochemistry, 10, 1529). Cells were weighed and 25 μ g 5- α -cholestane was added as internal standard. The samples are made alkaline with ammonia (10 % (v/v), 1 ml) and water (2 ml) is added. Alkaloids were extracted by vortexing with 2 ml of dichloromethane. After 30 min the samples were centrifuged (2000 rpm, 10 min) and the lower organic layer was separated and transferred into glass vials. After evaporation to dryness 25 μ l of dichloromethane was added and the samples were silylated with N-methyl-N-(trimethylsilyl)trifluoroacetamide (Pierce, Rockford, USA) for 20 min at 120 $^{\circ}$ C prior to GC-MS analysis. For alkaloid determination in the medium, 20 ml of the filtered medium was made alkaline with ammonia (10% v/v) to reach pH 9. Internal standards were added (5- α -cholestane and

cotinine). Subsequently this solution was extracted twice with dichloromethane (1:1) and evaporated to dryness. The column was rinsed twice with 1 ml of dichloromethane and the extract was transferred into glass vials. We further proceeded as described above for the cell extract.

5

Table 2. Alkaloid accumulation in transformed BY-2 cells ^a					
BY-2 Strain	Nicotine ^b		Anatabine ^b		
	Medium	Cells	Medium	Cells	% in medium
GUS	0	2.00	0.18	157	0.1
ScPDR5-US50	0	0.88	7.40	207	3.6
ScPDR5-W303	0	2.03	5.12	74	6.9

10

^a Measured 72 hours after elicitation with 50 μ M methyl jasmonate. Results are the mean of three independent experiments

^b Indicated in μ g/flask, with 20-ml BY-2 culture per flask

15

In jasmonate elicited BY-2 cells the alkaloids detected after 72 hours are nicotine, anabasine, anatabine and anattaline. No alkaloids are detected in DMSO-treated samples, neither in the cells nor in the medium. The results for nicotine and anatabine are shown in Table 2. Of all alkaloids that are produced by elicited BY-2 cells only anatabine is found in the medium. Although only trace amounts of anatabine can be detected extracellularly, comparison of anatabine levels in the different BY-2 cell lines after 72 hours of MeJA treatment clearly shows an enhancement of anatabine export in cell lines transformed with the *PDR5* genes.

20

25 EXAMPLE 4: Expression of vacuole targeted PDR5 in tobacco BY-2 suspension cultured cells

4.1 Construction and cloning of recombinant PDR5

To target the yeast PDR5 protein to plant vacuolar membranes two strategies are followed. In the first the N-terminal signal peptide and pro-peptide from sweet potato (MKAF¹TLALFLALSLYLLPNPAHSR²FNPIRLPTTHEPA, Matsuoka and Nakamura (1991) Proc. Natl. Acad. Sci. USA 88, 834) are fused at the N-terminus of the Pdr5 protein. The resulting recombinant open reading frame is designated ScNVacPDR5. In the second approach the C-terminal amino acids of the tobacco chitinase A (DLLGNGLLVDTM, Neuhaus et al. (1991) Proc. Natl. Acad. Sci. USA 88, 10362) are

30

added at the C-terminus of the Pdr5 protein. The resulting recombinant open reading frame is designated ScPDR5CVac. Both recombinant genes are put under the control of the CaMV35S promoter and cloned in the binary vector bearing the HYG and GFP genes as described in example 3.1. The resulting binary plasmids are designated pH-ScNVacPDR5-GFP and pH-ScPDR5CVac-GFP, respectively.

4.2 Effect of recombinant PDR5 expression in BY-2 suspension cultured cells on alkaloid tolerance and nicotine production

BY-2 suspension cultured cells are transformed as described in example 3.2 and 5 transgene calli of both ScNVacPDR5 or ScPDR5CVac transformed cells and highly expressing GFP are selected as described in example 3.3. Control of expression of recombinant PDR5 is performed as described in example 3.3 by northern and western blot analysis. Fractionation shows that in both types of transgene lines (NVac or CVac) the Pdr5 protein is targeted to the vacuolar membrane.

To assess tolerance to nicotine and hyoscyamine in transgenic cell lines the same assays as described in example 3.3 are used here to evaluate the functionality of vacuole targeted Pdr5p. The effect of the vacuolar expression of *PDR5* on nicotine production in BY-2 cells is evaluated as described in example 3.4.

EXAMPLE 5: Expression of plant PDR orthologues in tobacco BY-2 suspension cultured cells

5.1. Cloning of AtPDR1

The ABC protein super-family is the largest protein family known and most are membrane proteins active in the transport of a broad range of substances across the membranes. Also in *Arabidopsis* this superfamily is large and diverse (129 ORFs) and a complete inventory has been described by Sanchez-Fernandez et al. (J. Biol. Chem. (2001), 276, 30231). One of the subfamilies of full-length ABC transporters in *Arabidopsis* consists of the PDRs (13 ORFs) of which yeast *PDR5* is the prototype. At least eight of the *PDR5*-like ORFs in *Arabidopsis* are transcriptionally active and have been isolated as ESTs (Sanchez-Fernandez et al. (2001), J. Biol. Chem., 276, 30231). Amongst these is one of the closest *Arabidopsis* PDR5-orthologues, namely the *AtPDR1* gene (At3g16340). A cDNA clone of the *AtPDR1* gene is isolated as described for the yeast *PDR5* gene in example 3. To this end the following oligonucleotides were designed: 5'-AAAAAGCAGGCTACCATGGAGACGTTATCGAGAA-3' as the forward primer and 5'-

AGAAAGCTGGGTCTATCGTTGTTGGAAGTTGAGC-3' as the reverse primer, respectively. As a template we used cDNA prepared from *Arabidopsis* hypocotyls.

5.2 Cloning of HmPDR1

The biosynthesis of tropane alkaloids such as hyoscyamine and scopolamine in plants of the Solanaceae is very tissue-specific and occurs only in the roots. Later on the alkaloids are transported to the aerial parts, especially the leaves, where they are finally accumulated. In hairy roots however this translocation cannot occur and part of the produced alkaloids are released in the medium. This release can be stimulated by the addition of millimolar amounts of CdCl₂ to the medium (Furze et al. (1991) Plant Cell Rep. 10, 111 and Pitta-Alvarez et al. (2000) Enzyme. Microb. Technol. 26, 252). This indicates the existence of active detoxifying mechanisms against cadmium in which also the tropane alkaloids would be involved. We applied this knowledge to isolate an alkaloid specific PDR-like gene from *Hyoscyamus muticus* hairy roots.

A cDNA clone of a PDR-like gene is isolated from *H. muticus* and is designated HmPDR1. To this end total RNA was prepared from hairy roots of the *H. muticus* KB7 line (Jouhikainen et al. (1999) Planta 208, 545) treated for 30 hours with 1 mM CdCl₂ and was reverse transcribed with the Superscript RTII reverse transcriptase. A nested PCR was subsequently carried out with the *Taq* DNA polymerase using the DNA-RNA hybrid as the template and two sets of degenerate primers designed from highly conserved amino acid sequences in the nucleotide binding folds of known yeast and plant PDR proteins (see Table 3). This PCR yields two fragments derived from the two nucleotide-binding folds which are naturally present in the general tandem repeat structure of ABC proteins. Using specific primers and RT-PCR, 5'RACE and 3'RACE techniques we cloned a full-length cDNA clone, which is designated HmPDR1. The nucleotide sequence of the HmPDR1 cDNA clone is depicted in SEQ ID NO: 1, the amino acid sequence of the HmPDR1 protein is depicted in SEQ ID NO: 2.

Table 3. Degenerate primers used for HmPDR1 cDNA cloning

Primer	Sequence
ALGG39	5'-CCIRGYKCIGGIAARACNAC-3'
ALGG40	5'-ACICKYTTYTTYTGNCNCC-3'
ALGG41	5'-TCNARNCC-3'
ALGG42	5'-GGIGTIYTIACIGCNYTNATGGG-3'
ALGG43	5'-TCNARCATCCAIGTIGCNGGRTT-3'
ALGG44	5'-CKCCARTA-3'

To confirm the postulated relationship between the expression of ABC transporter genes and the CdCl₂ induced release of alkaloids we performed an expression analysis of the HmPDR1 gene in CdCl₂ treated *Hyoscyamus* hairy roots (Fig. 3).

5 Quantitative RT-PCR clearly showed that HmPDR1 is upregulated by CdCl₂ elicitation.

5.3 Effect of heterologous AtPDR1 expression in yeast cells on alkaloid tolerance

The *AtPDR1* gene was subcloned in a yeast expression vector (YCp50) between the 5' and 3' regulatory sequences of the yeast *PDR5* gene. This plasmid was then introduced in the yeast AD3 strain (the *pdr5* mutant, see example 1). To analyze the
10 substrate specificity of this plant PDR gene we controlled growth performance of the transformed yeast strains on YPD plates containing the different TAs and NAs as described in example 1. We have shown that the *PDR1* gene of *A. thaliana* was able to restore the growth of the *pdr5* mutant strain on hyoscyamine and nicotine.

5.4 Effect of heterologous AtPDR1 expression in BY-2 suspension cultured cells on
15 alkaloid tolerance

The *AtPDR1* gene was transferred to the binary vector pK7WGD2 as described in example 3.1. BY-2 suspension cultured cells were transformed as described in example 3.2. Control of expression of *AtPDR1* is performed by northern blot analysis using a specific DNA probe. To assess tolerance to nicotine and hyoscyamine in
20 transgenic cell lines the same assays as described in example 3.3 were performed in order to evaluate the functionality of AtPDR1p. Transgenic BY-2 cells showed enhanced tolerance to alkaloids as compared to the control GUS expressing line. However, not to the extent of the ScPDR5-W303 expressing line but comparable to the tolerance levels obtained in the ScPDR5-US50 line.

25

5.5 Effect of AtPDR1 expression in BY-2 suspension cultured cells on nicotinic alkaloid production

For the analysis of nicotinic alkaloid accumulation 6-days old recombinant BY-2 cell cultures (pK7WGD2-AtPDR1 en pK7WGD2-GUS) are washed and diluted ten-fold with
30 fresh hormone free MSST medium. After a recuperation period of 12 hours, the cells are treated with methyl jasmonate (MeJA). MeJA is dissolved in dimethyl sulfoxide (DMSO) and added to the culture medium at a final concentration of 50 µM. As a control, cells treated with an equivalent amount of DMSO are included. For alkaloid analysis the same process is followed as in example 3.4.

Claims

1. Use of an expression cassette comprising a gene encoding an ABC-transporter to induce or to enhance the production or the secretion of at least one secondary metabolite by plant cells comprising:
 - 5 - transforming said plant cells with an expression vector comprising said expression cassette,
 - selecting transformed plant cells with an induced or enhanced production or secretion of at least one secondary metabolite, and
 - propagating such selected transformed cells.
- 10 2. Use of an expression cassette according to claim 1 wherein the induction or enhancement of the production of at least one secondary metabolite by plant cells results from enhancing the transport of said metabolite into the vacuole.
3. Use of an expression cassette comprising a gene encoding an ABC-transporter to stimulate the production of secondary metabolites by plants comprising:
 - 15 - transforming said plants with an expression vector comprising said expression cassette,
 - selecting transformed plants with an enhanced production, and
 - propagating such selected transformed plants.
4. Use according to claims 1-3 wherein said secondary metabolites are alkaloids.
- 20 5. Use according to claims 1-3 wherein said ABC-transporters are derived from plants, fungal or mammalian cells.
6. A transgenic plant cell culture, with an enhanced production or secretion of an at least one secondary metabolite, transformed with an expression vector comprising an expression cassette according to claim 1.
- 25 7. A transgenic plant, the cells, seeds and progeny thereof which have an enhanced production or secretion of an at least one secondary metabolite, transformed with an expression vector comprising an expression cassette according to claim 3.
8. A transgenic plant cell culture according to claim 6 further characterized in (1) having an increased vacuolar localisation of said secondary metabolite, or (2)
 - 30 having a secretion or an increased secretion of said secondary metabolite.
9. A transgenic plant according to claim 7 further characterized in having an increased vacuolar localisation of said secondary metabolite.

10. An isolated polypeptide selected from the groups consisting of:

- a. an isolated polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO: 1;
- b. an isolated polypeptide comprising a polypeptide sequence having a
5 least 83 % identity to the polypeptide sequence of SEQ ID NO: 2;
- c. fragments and variants of such polypeptides in (a) to (b) that induce or enhance the production or the secretion of at least one secondary metabolite in plants or plant cells.

11. An isolated polynucleotide selected from the groups consisting of:

- a. an isolated polynucleotide comprising a polynucleotide sequence of SEQ
10 ID NO: 1;
- b. an isolated polynucleotide comprising a polynucleotide sequence having at least 91% identity to SEQ ID NO: 1;
- c. fragments and variants of such polynucleotides in (a) to (b) that induce or
15 enhance the production or the secretion of at least one secondary metabolite in plants or plant cells.

20

25

30

Fig. 1




Fig. 2





Fig. 3



V082.ST25.txt
SEQUENCE LISTING

<110> VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW

<120> THE USE OF GENES ENCODING MEMBRANE TRANSPORTER PUMPS TO STIMULATE THE PRODUCTION OF SECONDARY METABOLITES IN BIOLOGICAL CELLS

<130> DI/ABC/V082

<150> EP01201407.2

<151> 2001-04-18

<160> 15

<170> PatentIn version 3.1

<210> 1

<211> 4571

<212> DNA

<213> *Hyoscyamus muticus*

<220>

<221> CDS

<222> (133)..(4407)

<223>

<400> 1

atataactaa cttcaccttc tattcattca ttatcaacaa aataatccat tttttatcaa	60
aacttgaagg tggtgttaca agacacaact aatattaatt gctgcatttt aatttaattct	120
tggtgttcca ac atg gag cca tca gat tta agt aat ttc cga ggt cga agt	171
Met Glu Pro Ser Asp Leu Ser Asn Phe Arg Gly Arg Ser	
1 5 10	
atg aga gga agt atg aga gga agt gta agg gaa aat agt aac tca ata	219
Met Arg Gly Ser Met Arg Gly Ser Val Arg Glu Asn Ser Asn Ser Ile	
15 20 25	
tgg agg aac aat gga gtt gaa ata ttt tca aga tca act aga gat gaa	267
Trp Arg Asn Asn Gly Val Glu Ile Phe Ser Arg Ser Thr Arg Asp Glu	
30 35 40 45	
gat gat gaa gag gca tta aaa tgg gca gca ctt gag aaa tta cca aca	315
Asp Asp Glu Glu Ala Leu Lys Trp Ala Ala Leu Glu Lys Leu Pro Thr	
50 55 60	
tat gat aga tta aga aaa ggt ata ttg ttt gga tca caa ggt act ggt	363
Tyr Asp Arg Leu Arg Lys Gly Ile Leu Phe Gly Ser Gln Gly Thr Gly	
65 70 75	
gtt gct gaa gtt gat gta gat gat ctt ggt gtt caa caa agg aag aat	411
Val Ala Glu Val Asp Val Asp Asp Leu Gly Val Gln Gln Arg Lys Asn	
80 85 90	
ttg ctt gac aga ctt gtt aaa att gct gaa gaa gat aat gag aag ttc	459
Leu Leu Asp Arg Leu Val Lys Ile Ala Glu Glu Asp Asn Glu Lys Phe	
95 100 105	
ttg ttg aaa ctc aag aac agg att gac agg gtt ggg att gat ttt cca	507
Leu Leu Lys Leu Lys Asn Arg Ile Asp Arg Val Gly Ile Asp Phe Pro	
110 115 120 125	
tct ata gaa gtg aga ttt gag cat ctg aat att gag gca gat gca tat	555
Ser Ile Glu Val Arg Phe Glu His Leu Asn Ile Glu Ala Asp Ala Tyr	
130 135 140	

V082.ST25.txt

ggt ggt agc aga gct ttg cct aca ttt acc aac ttc att tct aac ttc Val Gly Ser Arg Ala Leu Pro Thr Phe Thr Asn Phe Ile Ser Asn Phe 145 150 155	603
att gag tcc ctg ctg gat tca ctt cac atc ctt cca tcg aaa aaa cgt Ile Glu Ser Leu Leu Asp Ser Leu His Ile Leu Pro Ser Lys Lys Arg 160 165 170	651
tca gtt aca att ctg aag gat gtt agt ggt atc gtc aag ccc tgt cga Ser Val Thr Ile Leu Lys Asp Val Ser Gly Ile Val Lys Pro Cys Arg 175 180 185	699
atg act ctg ctt tta gga cct cca ggt tct ggg aaa aca act ttg tta Met Thr Leu Leu Leu Gly Pro Pro Gly Ser Gly Lys Thr Thr Leu Leu 190 195 200 205	747
ctt gct ttg gct gga aaa ctt gat tct gct cta agg gtt acg ggg aag Leu Ala Leu Ala Gly Lys Leu Asp Ser Ala Leu Arg Val Thr Gly Lys 210 215 220	795
gtg acg tat aat gga cac gaa tta cat gaa ttt gtg cca caa aga act Val Thr Tyr Asn Gly His Glu Leu His Glu Phe Val Pro Gln Arg Thr 225 230 235	843
gcg gcc tat att agc cag cat gat ttg cat att gga gaa atg act gtc Ala Ala Tyr Ile Ser Gln His Asp Leu His Ile Gly Glu Met Thr Val 240 245 250	891
aga gaa act ttg gag ttc tct gca aga tgc caa gga gtt ggt tct cgt Arg Glu Thr Leu Glu Phe Ser Ala Arg Cys Gln Gly Val Gly Ser Arg 255 260 265	939
tac gaa atg ttg gcc gaa ctg tca aga aga gag aaa gcg gct aat atc Tyr Glu Met Leu Ala Glu Leu Ser Arg Arg Glu Lys Ala Ala Asn Ile 270 275 280 285	987
aaa cca gat gct gat att gac atg ttc atg aag gct gca tca act gaa Lys Pro Asp Ala Asp Ile Asp Met Phe Met Lys Ala Ala Ser Thr Glu 290 295 300	1035
ggg caa gaa gcc aaa gtg att act gat tat gtt ctt aag att ctg gga Gly Gln Glu Ala Lys Val Ile Thr Asp Tyr Val Leu Lys Ile Leu Gly 305 310 315	1083
ctg gat att tgt gca gat act atg gtg gga gat caa atg ata agg ggt Leu Asp Ile Cys Ala Asp Thr Met Val Gly Asp Gln Met Ile Arg Gly 320 325 330	1131
att tca gga gga cag aag aag cgt gtc act act ggt gaa atg att gtc Ile Ser Gly Gly Gln Lys Lys Arg Val Thr Thr Gly Glu Met Ile Val 335 340 345	1179
gga ccg tct aaa gcc ctt ttc atg gat gaa att tca act gga ctt gac Gly Pro Ser Lys Ala Leu Phe Met Asp Glu Ile Ser Thr Gly Leu Asp 350 355 360 365	1227
agt tcc aca act tac tcc atc gtg aat tcc cta aag caa tct gtt caa Ser Ser Thr Thr Tyr Ser Ile Val Asn Ser Leu Lys Gln Ser Val Gln 370 375 380	1275
atc ttg aaa gga aca gct ctg att tct ctc ttg cag cct gcc ccc gag Ile Leu Lys Gly Thr Ala Leu Ile Ser Leu Leu Gln Pro Ala Pro Glu 385 390 395	1323
act tac aac ttg ttc gat gat att gtt ctg cta tca gat ggc tac att Thr Tyr Asn Leu Phe Asp Asp Ile Val Leu Leu Ser Asp Gly Tyr Ile 400 405 410	1371

V082.ST25.txt

gtt tat cag ggt cca cga gag gaa gtg ctc gat ttc ttt gaa tcc atg	1419
Val Tyr Gln Gly Pro Arg Glu Glu Val Leu Asp Phe Phe Glu Ser Met	
415 420 425	
gga ttc aaa tgc ccc aac aga aaa ggc gtg gct gac ttc ttg caa gaa	1467
Gly Phe Lys Cys Pro Asn Arg Lys Gly Val Ala Asp Phe Leu Gln Glu	
430 435 440 445	
gtt aca tct aag aag gat caa cag caa tat tgg gta aag agg gac gag	1515
Val Thr Ser Lys Lys Asp Gln Gln Gln Tyr Trp Val Lys Arg Asp Glu	
450 455 460	
cct tat agg ttt att aca tca aaa gaa ttt gct gag gct tat caa tct	1563
Pro Tyr Arg Phe Ile Thr Ser Lys Glu Phe Ala Glu Ala Tyr Gln Ser	
465 470 475	
ttc cat gtt ggg aga aaa gta agc gat gaa ctt aca acc gca ttt gac	1611
Phe His Val Gly Arg Lys Val Ser Asp Glu Leu Thr Thr Ala Phe Asp	
480 485 490	
aag agc aaa agc cac cct gct gct ttg act act gaa aag tat ggt att	1659
Lys Ser Lys Ser His Pro Ala Ala Leu Thr Thr Glu Lys Tyr Gly Ile	
495 500 505	
gga gtg aaa caa ctt ttg aag gtt tgc acg gaa aga gag ttc ctt cta	1707
Gly Val Lys Gln Leu Leu Lys Val Cys Thr Glu Arg Glu Phe Leu Leu	
510 515 520 525	
atg cag agg aat tca ttt gtt tac atc ttc aaa ttc ttt cag ctt atg	1755
Met Gln Arg Asn Ser Phe Val Tyr Ile Phe Lys Phe Phe Gln Leu Met	
530 535 540	
gta att gca ctt atg aca atg acc ata ttt ttt cga act aag atg tct	1803
Val Ile Ala Leu Met Thr Met Thr Ile Phe Phe Arg Thr Lys Met Ser	
545 550 555	
cgg gat act gag acc gat gga gga att tat tct ggt gct ctc ttt ttt	1851
Arg Asp Thr Glu Thr Asp Gly Gly Ile Tyr Ser Gly Ala Leu Phe Phe	
560 565 570	
acg gtt gtt atg ctt atg ttt aat ggt ttg tct gag ctt cct ttg aca	1899
Thr Val Val Met Leu Met Phe Asn Gly Leu Ser Glu Leu Pro Leu Thr	
575 580 585	
ctc tac aag ctc ccg gtc ttc tac aag caa agg gac ttt ctc ttc tat	1947
Leu Tyr Lys Leu Pro Val Phe Tyr Lys Gln Arg Asp Phe Leu Phe Tyr	
590 595 600 605	
cct tca tgg gct tat gca gtt cct tca tgg atc cta aaa atc cct gta	1995
Pro Ser Trp Ala Tyr Ala Val Pro Ser Trp Ile Leu Lys Ile Pro Val	
610 615 620	
act ttt ctt gaa gtt ggg atg tgg gtg ttt ctc acc tat tat gtc atc	2043
Thr Phe Leu Glu Val Gly Met Trp Val Phe Leu Thr Tyr Tyr Val Ile	
625 630 635	
gga ttt gat cct aat gtt gga aga ttt ttc aaa caa ttt ttg cta ctc	2091
Gly Phe Asp Pro Asn Val Gly Arg Phe Phe Lys Gln Phe Leu Leu Leu	
640 645 650	
ata gta gta aac cag atg gca tca gga ttg ttc agg ttt att gca gca	2139
Ile Val Val Asn Gln Met Ala Ser Gly Leu Phe Arg Phe Ile Ala Ala	
655 660 665	
gtt gga agg acc atg gga gtt gct agc aca ttt gga gca ttt gcg ctg	2187
Val Gly Arg Thr Met Gly Val Ala Ser Thr Phe Gly Ala Phe Ala Leu	
670 675 680 685	

V082.ST25.txt

ctt tta caa ttt gca ttg ggc ggt ttt gtc ctt gca cga act gac gtg Leu Leu Gln Phe Ala Leu Gly Gly Phe Val Leu Ala Arg Thr Asp Val 690 695 700	2235
aag gac tgg tgg att tgg gga tac tgg acc tca cca ctt atg ttc tca Lys Asp Trp Trp Ile Trp Gly Tyr Trp Thr Ser Pro Leu Met Phe Ser 705 710 715	2283
gtg aat gca atc ctt gtg aat gaa ttt gac gga aaa aag tgg aaa cat Val Asn Ala Ile Leu Val Asn Glu Phe Asp Gly Lys Lys Trp Lys His 720 725 730	2331
att gcg cca aat gga act gag ccg ctt gga cct gca gtg gta aga tct Ile Ala Pro Asn Gly Thr Glu Pro Leu Gly Pro Ala Val Val Arg Ser 735 740 745	2379
caa ggg ttc ttt ccc gat gca tat tgg tac tgg ata ggt gta ggt gca Gln Gly Phe Phe Pro Asp Ala Tyr Trp Tyr Trp Ile Gly Val Gly Ala 750 755 760 765	2427
ctt gtt gga ttc aca gtt ctg ttt aac ata gcc tac agt ctt gct ctc Leu Val Gly Phe Thr Val Leu Phe Asn Ile Ala Tyr Ser Leu Ala Leu 770 775 780	2475
gct tat ctt aac cca ttc gga aag cca caa gct aca att tca gaa gaa Ala Tyr Leu Asn Pro Phe Gly Lys Pro Gln Ala Thr Ile Ser Glu Glu 785 790 795	2523
agt gag agc aac gaa aat agt gaa tta tca acc cca ata gct agt aca Ser Glu Ser Asn Glu Asn Ser Glu Leu Ser Thr Pro Ile Ala Ser Thr 800 805 810	2571
acg gaa gga gat tct gtc ggt gag aat cag aat aag aaa gga atg gtt Thr Glu Gly Asp Ser Val Gly Glu Asn Gln Asn Lys Lys Gly Met Val 815 820 825	2619
ctt cca ttt gaa ccc cat tcc atc acc ttt gat gaa gtt gta tac tca Leu Pro Phe Glu Pro His Ser Ile Thr Phe Asp Glu Val Val Tyr Ser 830 835 840 845	2667
gtt gac atg cct ccg gaa atg aga gag caa ggt acc agt gac aat aga Val Asp Met Pro Pro Glu Met Arg Glu Gln Gly Thr Ser Asp Asn Arg 850 855 860	2715
ttg gta ctt ttg aag agt gtg agt gga gct ttc agg cca ggt gtt ctc Leu Val Leu Leu Lys Ser Val Ser Gly Ala Phe Arg Pro Gly Val Leu 865 870 875	2763
aca gct ctg atg gga gtt agt gga gcc ggt aaa aca aca ttg atg gat Thr Ala Leu Met Gly Val Ser Gly Ala Gly Lys Thr Thr Leu Met Asp 880 885 890	2811
gtc tta gct gga agg aaa act gga ggt tac att gac gga agc att aac Val Leu Ala Gly Arg Lys Thr Gly Gly Tyr Ile Asp Gly Ser Ile Asn 895 900 905	2859
att tct gga tat ccc aag aag caa gaa aca ttt gca cgt att tct gga Ile Ser Gly Tyr Pro Lys Lys Gln Glu Thr Phe Ala Arg Ile Ser Gly 910 915 920 925	2907
tac tgt gaa caa aac gac atc cat tca cct tat gta aca gtt tat gag Tyr Cys Glu Gln Asn Asp Ile His Ser Pro Tyr Val Thr Val Tyr Glu 930 935 940	2955
tcc ttg gtt tac tcg gct tgg ctg cgt tta cct caa gac gtt gat gag Ser Leu Val Tyr Ser Ala Trp Leu Arg Leu Pro Gln Asp Val Asp Glu 945 950 955	3003

V082.ST25.txt

aaa aag cga atg atg ttc gtt gaa caa gtt atg gaa ctt gtg gag ctt Lys Lys Arg Met Met Phe Val Glu Gln Val Met Glu Leu Val Glu Leu 960 965 970	3051
aca cca cta aga tct gcc tta gtc ggg ttg cca gga gtt aat ggt ctg Thr Pro Leu Arg Ser Ala Leu Val Gly Leu Pro Gly Val Asn Gly Leu 975 980 985	3099
acg att gca gtt gaa cta gta gca aac ccc tct atc att ttt atg gac Thr Ile Ala Val Glu Leu Val Ala Asn Pro Ser Ile Ile Phe Met Asp 990 995 1000 1005	3147
gaa cca act tca gga ttg gat gca aga gct gct gca att gtg atg Glu Pro Thr Ser Gly Leu Asp Ala Arg Ala Ala Ala Ile Val Met 1010 1015 1020	3192
aga gct gtt agg aac act gtc gat aca ggg aga act gtt gtt tgt Arg Ala Val Arg Asn Thr Val Asp Thr Gly Arg Thr Val Val Cys 1025 1030 1035	3237
acc att cat cag cct agc att gac att ttt gag gcg ttc gat gag Thr Ile His Gln Pro Ser Ile Asp Ile Phe Glu Ala Phe Asp Glu 1040 1045 1050	3282
tta ttt ctt atg aaa cga gga gga caa gag ata tac gtc ggt cca Leu Phe Leu Met Lys Arg Gly Gly Gln Glu Ile Tyr Val Gly Pro 1055 1060 1065	3327
tta ggt cgt gag tca agc cat ttg ata aag tat ttt gag tct ata Leu Gly Arg Glu Ser Ser His Leu Ile Lys Tyr Phe Glu Ser Ile 1070 1075 1080	3372
ccc ggt gta acc aaa ata aag gag ggg tac aat cca gca act tgg Pro Gly Val Thr Lys Ile Lys Glu Gly Tyr Asn Pro Ala Thr Trp 1085 1090 1095	3417
atg tta gaa gtc aca tct tcg tct caa gaa ata aca tta ggt gtt Met Leu Glu Val Thr Ser Ser Ser Gln Glu Ile Thr Leu Gly Val 1100 1105 1110	3462
gat ttt acc gaa tta tac aag aac tca gac ctc ttc cgg agg aac Asp Phe Thr Glu Leu Tyr Lys Asn Ser Asp Leu Phe Arg Arg Asn 1115 1120 1125	3507
aaa gct ttg atc gag gaa cta agt gtg cca cgc cct ggt aca agt Lys Ala Leu Ile Glu Glu Leu Ser Val Pro Arg Pro Gly Thr Ser 1130 1135 1140	3552
gac ctg cat ttt gaa act gaa ttc tca cag cca ttt tgg gtc caa Asp Leu His Phe Glu Thr Glu Phe Ser Gln Pro Phe Trp Val Gln 1145 1150 1155	3597
tgt atg gct tgt ttg tgg aag caa cac tgg tca tac tgg cgt aat Cys Met Ala Cys Leu Trp Lys Gln His Trp Ser Tyr Trp Arg Asn 1160 1165 1170	3642
ccg gct tat act gca gtc aga ttt ctc ttc aca acc ttc ata gct Pro Ala Tyr Thr Ala Val Arg Phe Leu Phe Thr Thr Phe Ile Ala 1175 1180 1185	3687
ctc ata ttc ggg tca atg ttc tgg gat att ggt aca aaa gtg agt Leu Ile Phe Gly Ser Met Phe Trp Asp Ile Gly Thr Lys Val Ser 1190 1195 1200	3732
ggg ccc caa gat ctg aaa aac gcc atg gga tct atg tat gct gct Gly Pro Gln Asp Leu Lys Asn Ala Met Gly Ser Met Tyr Ala Ala 1205 1210 1215	3777

V082.ST25.txt

```

gtc ctc ttc ctt ggt  gtg cag aat tca tgc  tca gtt cag ccc gtt      3822
Val Leu Phe Leu Gly  Val Gln Asn Ser Ser  Ser Val Gln Pro Val
1220                               1230

gta tct gtc gaa cgt  act gta ttt tac aga  gaa aaa gct gct gga      3867
Val Ser Val Glu Arg  Thr Val Phe Tyr Arg  Glu Lys Ala Ala Gly
1235                               1245

atg tac tcc gcg atg  ccc tat gcc ttt gca  caa gtt ttc atc gaa      3912
Met Tyr Ser Ala Met  Pro Tyr Ala Phe Ala  Gln Val Phe Ile Glu
1250                               1255

att cct tat gta ttt  gta caa gct gtt gtc  tat ggt ctc att gtc      3957
Ile Pro Tyr Val Phe  Val Gln Ala Val Val  Tyr Gly Leu Ile Val
1265                               1270

tat tct atg att gga  ttt gaa tgg act gct  gca aaa ttc ttt tgg      4002
Tyr Ser Met Ile Gly  Phe Glu Trp Thr Ala  Ala Lys Phe Phe Trp
1280                               1285

tac ttc ttc ttc atg  ttc ttc acc ttc ctc  tac ttc acc ttc ttt      4047
Tyr Phe Phe Phe Met  Phe Phe Thr Phe Leu  Tyr Phe Thr Phe Phe
1295                               1300

ggc atg atg acc gtg  gct gtt acc ccg aac  caa aat gtt gct tca      4092
Gly Met Met Thr Val  Ala Val Thr Pro Asn  Gln Asn Val Ala Ser
1310                               1315

atc gtt gcc gga ttc  ttc tat aca gta tgg  aat ctc ttc tca gga      4137
Ile Val Ala Gly Phe  Phe Tyr Thr Val Trp  Asn Leu Phe Ser Gly
1325                               1330

ttc atc gtt cca cga  cct cgt att ccg ata  tgg tgg aga tgg tac      4182
Phe Ile Val Pro Arg  Pro Arg Ile Pro Ile  Trp Trp Arg Trp Tyr
1340                               1345

tac tgg gct tgc cct  gtt gca tgg aca ttg  tat ggt ttg gtt gca      4227
Tyr Trp Ala Cys Pro  Val Ala Trp Thr Leu  Tyr Gly Leu Val Ala
1355                               1360

tct caa ttt gga gac  ctc caa gat aca att  aat gat caa act gtg      4272
Ser Gln Phe Gly Asp  Leu Gln Asp Thr Ile  Asn Asp Gln Thr Val
1370                               1375

gaa gat ttc ttg aga  agt agc tat gga ttt  aag cat gat ttt cta      4317
Glu Asp Phe Leu Arg  Ser Ser Tyr Gly Phe  Lys His Asp Phe Leu
1385                               1390

gga gtt gtt gca gct  gtg atc gtt gca ttt  gca gtt gtt ttc gcc      4362
Gly Val Val Ala Ala  Val Ile Val Ala Phe  Ala Val Val Phe Ala
1400                               1405

ttc aca ttt gct ttg  ggt atc aag gca ttc  aat ttc cag aga aga      4407
Phe Thr Phe Ala Leu  Gly Ile Lys Ala Phe  Asn Phe Gln Arg Arg
1415                               1420

tagaaatagt atttatttgt attcccagtt gttcatatat tcttgaataa gcttatgaag  4467

ttttaagtta ctgaatatgt tatgtctttac taatctttct caattcccag ttttggttga  4527

taataacatg taataattgt tattcaaaaa aaaaaaaaaa aaaa  4571

```

```

<210> 2
<211> 1425
<212> PRT
<213> Hyoscyamus muticus

```

V082.ST25.txt

<400> 2

Met Glu Pro Ser Asp Leu Ser Asn Phe Arg Gly Arg Ser Met Arg Gly
 1 5 10 15

Ser Met Arg Gly Ser Val Arg Glu Asn Ser Asn Ser Ile Trp Arg Asn
 20 25 30

Asn Gly Val Glu Ile Phe Ser Arg Ser Thr Arg Asp Glu Asp Asp Glu
 35 40 45

Glu Ala Leu Lys Trp Ala Ala Leu Glu Lys Leu Pro Thr Tyr Asp Arg
 50 55 60

Leu Arg Lys Gly Ile Leu Phe Gly Ser Gln Gly Thr Gly Val Ala Glu
 65 70 75 80

Val Asp Val Asp Asp Leu Gly Val Gln Gln Arg Lys Asn Leu Leu Asp
 85 90 95

Arg Leu Val Lys Ile Ala Glu Glu Asp Asn Glu Lys Phe Leu Leu Lys
 100 105 110

Leu Lys Asn Arg Ile Asp Arg Val Gly Ile Asp Phe Pro Ser Ile Glu
 115 120 125

Val Arg Phe Glu His Leu Asn Ile Glu Ala Asp Ala Tyr Val Gly Ser
 130 135 140

Arg Ala Leu Pro Thr Phe Thr Asn Phe Ile Ser Asn Phe Ile Glu Ser
 145 150 155 160

Leu Leu Asp Ser Leu His Ile Leu Pro Ser Lys Lys Arg Ser Val Thr
 165 170 175

Ile Leu Lys Asp Val Ser Gly Ile Val Lys Pro Cys Arg Met Thr Leu
 180 185 190

Leu Leu Gly Pro Pro Gly Ser Gly Lys Thr Thr Leu Leu Leu Ala Leu
 195 200 205

Ala Gly Lys Leu Asp Ser Ala Leu Arg Val Thr Gly Lys Val Thr Tyr
 210 215 220

Asn Gly His Glu Leu His Glu Phe Val Pro Gln Arg Thr Ala Ala Tyr
 225 230 235 240

Ile Ser Gln His Asp Leu His Ile Gly Glu Met Thr Val Arg Glu Thr
 245 250 255

Leu Glu Phe Ser Ala Arg Cys Gln Gly Val Gly Ser Arg Tyr Glu Met

V082.ST25.txt

260

265

270

Leu Ala Glu Leu Ser Arg Arg Glu Lys Ala Ala Asn Ile Lys Pro Asp
 275 280 285

Ala Asp Ile Asp Met Phe Met Lys Ala Ala Ser Thr Glu Gly Gln Glu
 290 295 300

Ala Lys Val Ile Thr Asp Tyr Val Leu Lys Ile Leu Gly Leu Asp Ile
 305 310 315 320

Cys Ala Asp Thr Met Val Gly Asp Gln Met Ile Arg Gly Ile Ser Gly
 325 330 335

Gly Gln Lys Lys Arg Val Thr Thr Gly Glu Met Ile Val Gly Pro Ser
 340 345 350

Lys Ala Leu Phe Met Asp Glu Ile Ser Thr Gly Leu Asp Ser Ser Thr
 355 360 365

Thr Tyr Ser Ile Val Asn Ser Leu Lys Gln Ser Val Gln Ile Leu Lys
 370 375 380

Gly Thr Ala Leu Ile Ser Leu Leu Gln Pro Ala Pro Glu Thr Tyr Asn
 385 390 395 400

Leu Phe Asp Asp Ile Val Leu Leu Ser Asp Gly Tyr Ile Val Tyr Gln
 405 410 415

Gly Pro Arg Glu Glu Val Leu Asp Phe Phe Glu Ser Met Gly Phe Lys
 420 425 430

Cys Pro Asn Arg Lys Gly Val Ala Asp Phe Leu Gln Glu Val Thr Ser
 435 440 445

Lys Lys Asp Gln Gln Gln Tyr Trp Val Lys Arg Asp Glu Pro Tyr Arg
 450 455 460

Phe Ile Thr Ser Lys Glu Phe Ala Glu Ala Tyr Gln Ser Phe His Val
 465 470 475 480

Gly Arg Lys Val Ser Asp Glu Leu Thr Thr Ala Phe Asp Lys Ser Lys
 485 490 495

Ser His Pro Ala Ala Leu Thr Thr Glu Lys Tyr Gly Ile Gly Val Lys
 500 505 510

Gln Leu Leu Lys Val Cys Thr Glu Arg Glu Phe Leu Leu Met Gln Arg
 515 520 525

Asn Ser Phe Val Tyr Ile Phe Lys Phe Phe Gln Leu Met Val Ile Ala

V082.ST25.txt
540

530 535 540
 Leu Met Thr Met Thr Ile Phe Phe Arg Thr Lys Met Ser Arg Asp Thr
 545 550 555 560
 Glu Thr Asp Gly Gly Ile Tyr Ser Gly Ala Leu Phe Phe Thr Val Val
 565 570 575
 Met Leu Met Phe Asn Gly Leu Ser Glu Leu Pro Leu Thr Leu Tyr Lys
 580 585 590
 Leu Pro Val Phe Tyr Lys Gln Arg Asp Phe Leu Phe Tyr Pro Ser Trp
 595 600 605
 Ala Tyr Ala Val Pro Ser Trp Ile Leu Lys Ile Pro Val Thr Phe Leu
 610 615 620
 Glu Val Gly Met Trp Val Phe Leu Thr Tyr Tyr Val Ile Gly Phe Asp
 625 630 635 640
 Pro Asn Val Gly Arg Phe Phe Lys Gln Phe Leu Leu Leu Ile Val Val
 645 650 655
 Asn Gln Met Ala Ser Gly Leu Phe Arg Phe Ile Ala Ala Val Gly Arg
 660 665 670
 Thr Met Gly Val Ala Ser Thr Phe Gly Ala Phe Ala Leu Leu Leu Gln
 675 680 685
 Phe Ala Leu Gly Gly Phe Val Leu Ala Arg Thr Asp Val Lys Asp Trp
 690 695 700
 Trp Ile Trp Gly Tyr Trp Thr Ser Pro Leu Met Phe Ser Val Asn Ala
 705 710 715 720
 Ile Leu Val Asn Glu Phe Asp Gly Lys Lys Trp Lys His Ile Ala Pro
 725 730 735
 Asn Gly Thr Glu Pro Leu Gly Pro Ala Val Val Arg Ser Gln Gly Phe
 740 745 750
 Phe Pro Asp Ala Tyr Trp Tyr Trp Ile Gly Val Gly Ala Leu Val Gly
 755 760 765
 Phe Thr Val Leu Phe Asn Ile Ala Tyr Ser Leu Ala Leu Ala Tyr Leu
 770 775 780
 Asn Pro Phe Gly Lys Pro Gln Ala Thr Ile Ser Glu Glu Ser Glu Ser
 785 790 795 800
 Asn Glu Asn Ser Glu Leu Ser Thr Pro Ile Ala Ser Thr Thr Glu Gly

V082.ST25.txt

805

810

815

Asp Ser Val Gly Glu Asn Gln Asn Lys Lys Gly Met Val Leu Pro Phe
820 825 830

Glu Pro His Ser Ile Thr Phe Asp Glu Val Val Tyr Ser Val Asp Met
835 840 845

Pro Pro Glu Met Arg Glu Gln Gly Thr Ser Asp Asn Arg Leu Val Leu
850 855 860

Leu Lys Ser Val Ser Gly Ala Phe Arg Pro Gly Val Leu Thr Ala Leu
865 870 875 880

Met Gly Val Ser Gly Ala Gly Lys Thr Thr Leu Met Asp Val Leu Ala
885 890 895

Gly Arg Lys Thr Gly Gly Tyr Ile Asp Gly Ser Ile Asn Ile Ser Gly
900 905 910

Tyr Pro Lys Lys Gln Glu Thr Phe Ala Arg Ile Ser Gly Tyr Cys Glu
915 920 925

Gln Asn Asp Ile His Ser Pro Tyr Val Thr Val Tyr Glu Ser Leu Val
930 935 940

Tyr Ser Ala Trp Leu Arg Leu Pro Gln Asp Val Asp Glu Lys Lys Arg
945 950 955 960

Met Met Phe Val Glu Gln Val Met Glu Leu Val Glu Leu Thr Pro Leu
965 970 975

Arg Ser Ala Leu Val Gly Leu Pro Gly Val Asn Gly Leu Thr Ile Ala
980 985 990

Val Glu Leu Val Ala Asn Pro Ser Ile Ile Phe Met Asp Glu Pro Thr
995 1000 1005

Ser Gly Leu Asp Ala Arg Ala Ala Ala Ile Val Met Arg Ala Val
1010 1015 1020

Arg Asn Thr Val Asp Thr Gly Arg Thr Val Val Cys Thr Ile His
1025 1030 1035

Gln Pro Ser Ile Asp Ile Phe Glu Ala Phe Asp Glu Leu Phe Leu
1040 1045 1050

Met Lys Arg Gly Gly Gln Glu Ile Tyr Val Gly Pro Leu Gly Arg
1055 1060 1065

Glu Ser Ser His Leu Ile Lys Tyr Phe Glu Ser Ile Pro Gly Val

V082.ST25.txt

1070		1075		1080
Thr Lys Ile Lys Glu Gly Tyr Asn Pro Ala Thr Trp Met Leu Glu				
1085		1090		1095
Val Thr Ser Ser Ser Gln Glu Ile Thr Leu Gly Val Asp Phe Thr				
1100		1105		1110
Glu Leu Tyr Lys Asn Ser Asp Leu Phe Arg Arg Asn Lys Ala Leu				
1115		1120		1125
Ile Glu Glu Leu Ser Val Pro Arg Pro Gly Thr Ser Asp Leu His				
1130		1135		1140
Phe Glu Thr Glu Phe Ser Gln Pro Phe Trp Val Gln Cys Met Ala				
1145		1150		1155
Cys Leu Trp Lys Gln His Trp Ser Tyr Trp Arg Asn Pro Ala Tyr				
1160		1165		1170
Thr Ala Val Arg Phe Leu Phe Thr Thr Phe Ile Ala Leu Ile Phe				
1175		1180		1185
Gly Ser Met Phe Trp Asp Ile Gly Thr Lys Val Ser Gly Pro Gln				
1190		1195		1200
Asp Leu Lys Asn Ala Met Gly Ser Met Tyr Ala Ala Val Leu Phe				
1205		1210		1215
Leu Gly Val Gln Asn Ser Ser Ser Val Gln Pro Val Val Ser Val				
1220		1225		1230
Glu Arg Thr Val Phe Tyr Arg Glu Lys Ala Ala Gly Met Tyr Ser				
1235		1240		1245
Ala Met Pro Tyr Ala Phe Ala Gln Val Phe Ile Glu Ile Pro Tyr				
1250		1255		1260
Val Phe Val Gln Ala Val Val Tyr Gly Leu Ile Val Tyr Ser Met				
1265		1270		1275
Ile Gly Phe Glu Trp Thr Ala Ala Lys Phe Phe Trp Tyr Phe Phe				
1280		1285		1290
Phe Met Phe Phe Thr Phe Leu Tyr Phe Thr Phe Phe Gly Met Met				
1295		1300		1305
Thr Val Ala Val Thr Pro Asn Gln Asn Val Ala Ser Ile Val Ala				
1310		1315		1320
Gly Phe Phe Tyr Thr Val Trp Asn Leu Phe Ser Gly Phe Ile Val				

V082.ST25.txt

1325 1330 1335
 Pro Arg Pro Arg Ile Pro Ile Trp Trp Arg Trp Tyr Tyr Trp Ala
 1340 1345 1350
 Cys Pro Val Ala Trp Thr Leu Tyr Gly Leu Val Ala Ser Gln Phe
 1355 1360 1365
 Gly Asp Leu Gln Asp Thr Ile Asn Asp Gln Thr Val Glu Asp Phe
 1370 1375 1380
 Leu Arg Ser Ser Tyr Gly Phe Lys His Asp Phe Leu Gly Val Val
 1385 1390 1395
 Ala Ala Val Ile Val Ala Phe Ala Val Val Phe Ala Phe Thr Phe
 1400 1405 1410
 Ala Leu Gly Ile Lys Ala Phe Asn Phe Gln Arg Arg
 1415 1420 1425

<210> 3
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> forward primer in example 3.1

<400> 3
 aaaagcagg ctaccatgcc cgaggccaag cttaacaata

40

<210> 4
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> reverse primer of example 3.1

<400> 4
 agaaagctgg gtccatcttg gtaagtttct ttctttaacc

40

<210> 5
 <211> 37
 <212> PRT
 <213> Ipomoea batatas

<300>
 <301> Matsuoka and Nakamura
 <302> Propeptide of a precursor to a plant vacuolar protein required for vacuol
 ar
 targeting
 <303> Proc. Natl. Acad. Sci. USA
 <304> 88
 <305> 3
 <306> 834-8
 <307> 1991-02-01
 <308> PMID: 1992474
 <309> 1991-02-01

V082.ST25.txt

<313> (1) .. (37)

<400> 5

Met Lys Ala Phe Thr Leu Ala Leu Phe Leu Ala Leu Ser Leu Tyr Leu
 1 5 10 15

Leu Pro Asn Pro Ala His Ser Arg Phe Asn Pro Ile Arg Leu Pro Thr
 20 25 30

Thr His Glu Pro Ala
 35

<210> 6

<211> 12

<212> PRT

<213> Nicotiana tabacum

<300>

<301> Neuhaus, J.M.; Sticher, L.; Meins, F. and Boller, T.

<302> A short C-terminal sequence is necessary and sufficient for the targeting
 of
 chitinases to the plant vacuole

<303> Proc. Natl. Acad. Sci. USA

<304> 88

<305> 22

<306> 10362-10366

<307> 1991-11-15

<308> PMID: 1946457

<309> 1991-11-25

<313> (318) .. (329)

<400> 6

Asp Leu Leu Gly Asn Gly Leu Leu Val Asp Thr Met
 1 5 10

<210> 7

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> forward primer in example 5.1

<400> 7

aaaaagcagg ctaccatgga gacgttatcg agaa

34

<210> 8

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> reverse primer in example 5.1

<400> 8

agaaagctgg gtctatcggt gttggaagtt gagc

34

<210> 9

<211> 12789

<212> DNA

V082.ST25.txt

<213> Artificial Sequence

<220>

<223> vector pK7WG2D

<220>

<221> misc feature

<222> (4772)..(4772)

<223> n can be any base

<400> 9

tgatcacagg cagcaacgct ctgtcatcgt tacaatcaac atgctaccct ccgcgagatc	60
atccgtgttt caaaccggc agcttagttg ccgttcttcc gaatagcatc ggtaacatga	120
gcaaagtctg ccgccttaca acggctctcc cgctgacgcc gtcccggact gatgggctgc	180
ctgtatcgag tgggtatttt gtgccgagct gccggtcggg gagctgttg ctggctggtg	240
gcaggatata ttgtggtgta aacaaattga cgcttagaca acttaataac acattgcgga	300
cgtttttaat gtactgaatt aacgccgaat tgaattatca gcttgcattc cggctgatct	360
agtaacatag atgacaccgc gcgcgataat ttatcctagt ttgcgcgcta tattttgttt	420
tctatcgctg attaaatgta taattgctgg actctaatac aaaaacccat ctcataaata	480
acgtcatgca ttacatgtta attattacat gcttaacgta attcaacaga aattatatga	540
taatcatcgc aagaccggca acaggattca atcttaagaa actttattgc caaatgtttg	600
aacgatctgc ttgactctag cttagagtcg aaccccgag tcccgctcag aagaactcgt	660
caagaaggcg atagaaggcg atgcgctgcg aatcgggagc ggcgataccg taaagcacga	720
ggaagcggtc agccattcgc ccgccaagct ctccagcaat atcacgggta gccaacgcta	780
tgtcctgata gcggtccgcc acaccagcc ggccacagtc gatgaatcca gaaaagcggc	840
cattttccac catgatattc ggcaagcagg catcgccctg ggtcacgacg agatcctcgc	900
cgtcgggcat ccgcgccttg agcctggcga acagttcggc tggcgcgagc ccctgatgct	960
cttcgtccag atcatcctga tcgacaagac cggtctccat ccgagtacgt cctcgtcga	1020
tgcgatgttt cgcttggtgg tcgaatgggc aggtagccgg atcaagcgta tgcagccgcc	1080
gcattgcatt agccatgatg gatactttct cggcaggagc aaggtgagat gacaggagat	1140
cctgccccgg cacttcgccc aatagcagcc agtccttccc cgcttcagtg acaacgtcga	1200
gcacagctgc gcaaggaacg ccgctcgtgg ccagccacga tagccgcgct gcctcgtctt	1260
ggagttcatt cagggcaccg gacaggtcgg tcttgacaaa aagaaccggg cggccctgcg	1320
ctgacagccg gaacacggcg gcatcagagc agccgattgt ctgttggtgc cagtcatagc	1380
cgaatagcct ctccacccaa gcggccggag aacctgcgtg caatccatct tgttcaatca	1440
tgctcgtatc gagttgagag tgaatatgag actctaattg gataccgagg ggaatttatg	1500
gaacgtcagt ggagcatttt tgacaagaaa tatttgctag ctgatagtga ccttaggcga	1560
cttttgaaac cgcaataatg gttcttgacg tatgtgctta gtcattaaa ctccagaaac	1620
ccgcggtcga gtggctcctt caacgttgcg gttctgtcag ttccaaacgt aaaacggctt	1680

V082.ST25.txt

gtcccgctc atcggcgggg gtcataacgt gactccctta attctcatgt atgataattc	1740
gcggtacccg gggatcctct agagggcccg acgtcgcatg cctgcaggtc actggatttt	1800
ggtttttagga attagaaatt ttattgatag aagtatttta caaatacaaa tacatactaa	1860
gggtttctta tatgctcaac acatgagcga aaccctataa gaaccctaatt tcccttatct	1920
gggaactact cacacattat tctggagaaa aatagagaga gatagatttg tagagagaga	1980
ctggtgattt ttgcggaact tagcatggcc gcgggatatc accactttgt acaagaaagc	2040
tgaacgagaa acgtaaaatg atataaatat caatatatta aattagattt tgcataaaaa	2100
acagactaca taatactgta aaacacaaca tatccagtcga ctatggtcga cctgcagaact	2160
ggctgtgtat aaggagacct gacatttata ttccccagaa catcagggtta atggcgtttt	2220
tgatgtcatt ttcgcggtgg ctgagatcag ccactttctc cccgataacg gagaccggca	2280
cactggccat atcggtggc atcatgcgcc agctttctatc cccgatatgc accaccgggt	2340
aaagttcacg ggagacttta tctgacagca gacgtgcact ggccaggggg atcaccatcc	2400
gtcgcccggg cgtgtcaata atatcactct gtacatccac aaacagacga taacggctct	2460
ctcttttata ggtgtaaacc ttaaaactgca ttccaccagt cctgttctc gtcagcaaaa	2520
gagccgttca tttcaataaa ccgggcgacc tcagccatcc cttcctgatt ttccgcttct	2580
cagcgttcgg cagcagacg acgggcttca ttctgcatgg ttgtgcttac cagaccggag	2640
atattgacat catatatgcc ttgagcaact gatagctgtc gctgtcaact gtcactgtaa	2700
tacgtgctt catagcacac ctctttttga catacttcgg gtatacatat cagtatatat	2760
tcttataaccg caaaaatcag cgcgcaaata cgcatactgt tatctggctt ttagtaagcc	2820
ggatccacgc gtttacgccc cgccctgcc ctcacgcag tactgttgta attcattaag	2880
cattctgccc acatggaagc catcacagac ggcgatgatga acctgaatcg ccagcggcat	2940
cagcaccttg tcgccttgcg tataatattt gcccatggcg aaaacggggg cgaagaagtt	3000
gtccatattg gccacgttta aatcaaaact ggtgaaactc acccagggat tggctgagac	3060
gaaaaacata ttctcaataa accctttagg gaaataggcc aggttttcac cgtaacacgc	3120
cacatcttgc gaatatatgt gtagaaactg ccggaaatcg tcgtggtatt cactccagag	3180
cgatgaaaac gtttcagttt gtcctggaa aacgggtgaa caagggtgaa cactatccca	3240
tatcaccagc tcaccgtctt tcattgccat acggaattcc ggatgagcat tcacaggcg	3300
ggcaagaatg tgaataaagg ccggataaaa cttgtgctta tttttcttta cggctctttaa	3360
aaaggccgta atatccagct gaacggctctg gttataggta cattgagcaa ctgactgaaa	3420
tgctcaaaa tgttctttac gatgccattg ggatatatca acggtggtat atccagtgat	3480
ttttttctcc attttagctt ccttagctcc tgaaaatctc gccggatcct aactcaaaat	3540
ccacacatta tacgagccgg aagcataaag tgtaaaagcct ggggtgccta atgcggccgc	3600
catagtgact ggatatgttg tgttttacag tattatgtag tctgtttttt atgcaaaatc	3660
taatttaata tattgatatt tatatcattt tacgtttctc gttcagcttt tttgtacaaa	3720

V082.ST25.txt

cttgtgatat cactagtgcg gccgcctgca ggtcgactag aatagtaa	3780
tttgttgttt gttttgttgt ggtaattggt gtaaaaatac ggatcgtcct gcagtcctct	3840
ccaaatgaaa tgaacttcct tataatagagg aagggtcttg cgaaggatag tgggattgtg	3900
cgtcatccct tacgtcagtg gagatatcac atcaatccac ttgctttgaa gacgtggttg	3960
gaacgtcttc tttttccacg atgctcctcg tgggtggggg tccatctttg ggaccactgt	4020
cggcagaggc atcttgaacg atagcctttc ctttatcgca atgatggcat ttgtagggtg	4080
caccttcctt ttctactgtc cttttgatga agtgacagat agctgggcaa tggaatccga	4140
ggaggtttcc cgatattacc ctttgttgaa aagtctcaat agcccttttg tcttctgaga	4200
ctgtatcttt gatattcttg gagtagacga gagtgctgtg ctccaccatg ttgacgaaga	4260
ttttcttctt gtcattgagt cgtaaaagac tctgtatgaa ctgttcgcca gtcttcacgg	4320
cgagtctgt tagatcctcg atctgaattt ttgactccat ggcctttgat tcagtaggaa	4380
ctactttctt agagactcca atctctatta cttgccttgg tttatgaagc aagccttgaa	4440
tcgtccatac tggaaatagta cttctgatct tgagaaatat atctttctct gtgttcttga	4500
tgcagttagt cctgaatctt ttgactgcat ctttaacctt cttgggaagg tatttgatct	4560
cctggagatt attactcggg tagatcgtct tgatgagacc tgccgcgtag gcctctctaa	4620
ccatctgtgg gtcagcattc tttctgaaat tgaagaggct aatcttctca ttatcggtgg	4680
tgaacatggt atcgtcacct tctccgtcga actttcttcc tagatcgtag agatagagaa	4740
agtcgtccat ggtgatctcc ggggcaaagg anatctcgac catatgggag agctcaagct	4800
tgcattgctg caggctactg gattttgggt ttaggaatta gaaattttat tgatagaagt	4860
attttacaaa taaaaatata tactaagggt ttcttatatg ctcaacacat gagcgaaacc	4920
ctataagaac cctaattccc ttatgtggga actactcaca cattattctg gagaaaaata	4980
gagagagata gatttgtaga gagagactgg tgatttttgc ggactctaga actagtggat	5040
ccccgggct gcagccgggc ggcgcttaca gctcgctctt cttgtacagc tcgtccatgc	5100
cgagagtgat cccggcggcg gtcacgaact ccagcaggac catgtgatcg cgcttctcgt	5160
tgggtctctt gctcaggcg gactgggtgc tcaggtagtg gttgtcgggc agcagcacgg	5220
ggccgtcgcc gatgggggtg ttctgctggt agtggtcggc gagctgcacg ctgccgtcct	5280
cgatgttgtg gcggatcttg aagttcacct tgatgccgtt cttctgcttg tcggccatga	5340
tatagacgtt gtggctgttg tagttgtact ccagcttgtg cccaggatg ttgccgtcct	5400
ccttgaagtc gatgcccttc agctcgatgc ggttcaccag ggtgtcgccc tcgaacttca	5460
cctcggcgcg ggtctttag tagccgtcgt ccttgaagaa gatgggtgcg tcctggacgt	5520
agccttcggg catggcggac ttgaagaagt cgtgctgctt catgtggtcg gggtagcggc	5580
tgaagcactg cagcccgtag gtcagggtgg tcacgagggt gggccagggc acgggcagct	5640
tgccggtggt gcagatgaac ttcagggtca gcttgccgta ggtggcatcg ccctcgccct	5700
cgccggacac gctgaacttg tggccgttta cgtcgccgtc cagctcgacc aggatgggca	5760

V082.ST25.txt

ccaccccggt	gaacagctcc	tcgcccttgc	tcaccatgtc	ggccgaggat	aatgatagga	5820
gaagtgaaaa	gatgaaaaag	agaaaaagat	tagtcttcac	catggctatc	gttcgtaaat	5880
ggtgaaaatt	ttcagaaaaat	agctttttgct	ttaaaagaaa	tgatttaaat	tgctgcaata	5940
gaagtagaat	gcttgattgc	ttgagattcg	tttgttttgt	atatgttggtg	ttgagaattc	6000
gagctcggta	cccggggatc	ctctagcgaa	ttttctctgc	tcaaattggt	gagggttagcg	6060
gatttgtaaa	cgcgtttata	tgggctgctt	ggagggtact	tttggtattaa	ttttttctg	6120
ccagcgcatt	ctgacgcggc	accgcttttg	aaagtgcgct	gtgggtccgc	gttttctaca	6180
ataatgtgcc	gatccggtca	gaaagtatat	ggatgagttg	tgccagcctc	accaacgtgc	6240
tgaggccca	tcatgactac	ttcaatgtta	atgggggtaa	tgaataaata	ggcgaaattg	6300
ggttcacggt	gggcccagg	aatataatat	tgccgcagag	gtagtcggat	gccaaagccc	6360
gcaactaata	gttcacgaac	aaattcctag	agagtcgacc	tgacgcatgc	aagctaacct	6420
gcaggcatgc	aagcttagct	tgagcttggg	tcagattgtc	gtttcccgcc	ttcagtttaa	6480
actatcagtg	tttgacagga	tattattggcg	ggtaaacct	agagaaaaga	gcgtttatta	6540
gaataacgga	tatttaaaag	ggcgtgaaaa	ggtttatccg	ttcgtccatt	tgtatgtgca	6600
tgccaaccac	agggttcccc	tcgggatcaa	agtactttga	tccaacctct	ccgctgctat	6660
agtgcagtcg	gcttctgacg	ttcagtgacg	ccgtcttctg	aaaacgacat	gtcgcacaag	6720
tcctaagtta	cgcgacaggg	tgccgcctct	cccttttctc	ggcgttttct	tgtcgcgtgt	6780
tttagtcgca	taaagtagaa	tacttgcgac	tagaaccgga	gacattacgc	catgaacaag	6840
agcgccgccc	ctggcctgct	gggctatgcc	cgcgtcagca	ccgacgacca	ggacttgacc	6900
aaccaacggg	ccgaactgca	cgcggccggc	tgcaccaagc	tgttttccga	gaagatcacc	6960
ggcaccaggg	gcgaccgccc	ggagctggcc	aggatgcttg	accacctacg	ccctggcgac	7020
gttgtgacag	tgaccaggct	agaccgcctg	gcccgcagca	cccgcgacct	actggacatt	7080
gccgagcgca	tccaggaggc	cggcgcgggc	ctgcgtagcc	tggcagagcc	gtgggcccgc	7140
accaccacgc	cggccggccc	catggtgttg	accgtgttcg	ccggcattgc	cgagttcgag	7200
cgttccctaa	tcacgcagcg	caccgggagc	gggcgcgagg	ccgccaaggc	ccgaggcggtg	7260
aagtttgccc	cccgccctac	cctcaccctg	gcacagatcg	cgcacgcccc	cgagctgac	7320
gaccaggaag	gccgcaccgt	gaaagaggcg	gctgcactgc	ttggcggtgca	tcgctcgacc	7380
ctgtaccgcg	cacttgagcg	cagcgaggaa	gtgacgccc	ccgaggccag	gcggcgcggt	7440
gccttccgtg	aggacgcatt	gaccgaggcc	gacgccttgg	cggccgcccga	gaatgaacgc	7500
caagaggaac	aagcatgaaa	ccgcaccagg	acggccagga	cgaaccgttt	ttcattaccg	7560
aagagatcga	ggcggagatg	atcgcggccc	ggtacgtgtt	cgagccgccc	gcgcacgtct	7620
caaccgtgcg	gttgcattgaa	atcctggccg	gtttgtctga	tgcgaagctg	gcggcctggc	7680
cggccagctt	ggccgctgaa	gaaaccgagc	gccgcctct	aaaaagggtga	tgtgtatttg	7740
agtaaaacag	cttgcgctcat	gcggtcgctg	cgtatatgat	gcgatgagta	aataaaca	7800

V082.ST25.txt

tacgcaaggg gaacgcatga aggttatcgc tgtactttaac cagaaaggcg ggtcaggcaa	7860
gacgaccatc gcaacccatc tagcccgcgc cctgcaactc gccggggccg atgttctgtt	7920
agtcgattcc gatccccagg gcagtgcgcg cgattgggcg gccgtgcggg aagatcaacc	7980
gctaaccgtt gtcggcatcg accgcccgcg gattgaccgc gacgtgaagg ccatcggccg	8040
gcgcgacttc gtagtgatcg acggagcgcc ccaggcgcg gacttggctg tgtccgcgat	8100
caaggcagcc gacttcgtgc tgattccggt gcagccaagc ccttacgaca tatgggccac	8160
cgccgacctg gtggagctgg ttaagcagcg cattgaggtc acggatggaa ggctacaagc	8220
ggcctttgtc gtgtcgcggg cgatcaaagg cacgcgcac gccgggtgagg ttgccgaggc	8280
gctggccggg tacgagctgc ccattcttga gtcccgtatc acgcagcgcg tgagctaccc	8340
aggcactgcc gccgcccgcg caaccgttct tgaatcagaa cccgaggcg acgctgcccg	8400
cgagggtccag gcgctggccg ctgaaattaa atcaaaactc atttgagtta atgaggtaaa	8460
gagaaaaatga gcaaaagcac aaacacgcta agtgccggcc gtccgagcgc acgcagcagc	8520
aaggctgcaa cgttggccag cctggcagac acgccagcca tgaagcgggt caactttcag	8580
ttgccggcgg aggatcacac caagctgaag atgtacgcg tacgccaagg caagaccatt	8640
accgagctgc tatctgaata catcgcgcg ctaccagagt aaatgagcaa atgaataaat	8700
gagtagatga attttagcgg ctaaaggagg cggcatggaa aatcaagaac aaccaggcac	8760
cgacgccgtg gaatgcccc tgtgtggagg aacgggcggt tggccaggcg taagcggtg	8820
ggttgtctgc cgccctgca atggcactgg aacccccaa cccgaggaat cggcgtgacg	8880
gtcgcaaac atccggcccc gtacaaatcg gcgcggcgct gggtgatgac ctggtggaga	8940
agttgaaggc cgcgcaggcc gcccgcgcc aacgcacgca ggcagaagca cgccccggtg	9000
aatcgtggca agcggccgct gatcgaatcc gcaagaatc ccggcaaccg ccggcagccg	9060
gtgcgccgtc gattaggaag ccgcccagg gcgacgagca accagatttt ttcgttccga	9120
tgctctatga cgtgggcacc cgcgatagtc gcagcatcat ggacgtggcc gttttccgtc	9180
tgtcgaagcg tgaccgacga gctggcgagg tgatccgcta cgagcttcca gacgggcacg	9240
tagaggtttc cgcagggccg gccggcatgg ccagtgtgtg ggattacgac ctggtactga	9300
tggcggtttc ccatctaacc gaatccatga accgataccg ggaagggaag ggagacaagc	9360
ccggcccgct gttccgtcca caagttgcgg acgtactcaa gttctgccg cgagccgatg	9420
gcggaagca gaaagacgac ctggtagaaa cctgcattcg gttaaaccac acgcacgttg	9480
ccatgcagcg tacgaagaag gccagaacg gccgcctggt gacggtatcc gaggggtgaag	9540
ccttgattag ccgttacaag atcgtaaaga gcgaaaccgg gcggccggag tacatcgaga	9600
tcgagctagc tgattggatg taccgcgaga tcacagaagg caagaaccgg gacgtgctga	9660
cggttcacc ccattacttt ttgatcgatc ccggcatcgg ccgtttttct taccgcctgg	9720
cacgcgcgc cgcaggcaag gcagaagcca gatggttgtt caagacgac tacgaacgca	9780
gtggcagcgc cggagagttc aagaagttct gtttcaccgt gcgcaagctg atcgggtcaa	9840

V082.ST25.txt

```

atgacctgcc ggagtacgat ttgaaggagg aggcgggggca ggctggcccg atcctagtca 9900
tgcgctaccg caacctgata gagggcgaag catccgccgg ttcctaattgt acggagcaga 9960
tgctagggca aattgcccta gcaggggaaa aaggctgaaa aggtctcttt cctgtggata 10020
gcacgtacat tgggaaccca aagccgtaca ttgggaaccg gaaccctgtac attgggaacc 10080
caaagccgta cattgggaac cggtcacaca tgtaagtgtac tgatataaaa gagaaaaaag 10140
gcgatttttc cgctaaaaac tctttaaaaac ttattaaaaac tcttaaaaacc cgcttggcct 10200
gtgcataact gtctggccag cgcacagccg aagagctgca aaaagcgct acccttcggt 10260
cgctgcgctc cctacgcccc gccgcttcgc gtcggcctat cgcggccgct ggccgctcaa 10320
aaatggctgg cctacggcca ggcaatctac cagggcgcg acaagccgag ccgtcgccac 10380
tcgaccgccc gcgcccacat caaggcaccg tgcctcgcg gtttcggtga tgacggtgaa 10440
aacctctgac acatgcagct cccggagacg gtcacagctt gtctgtaagc ggatgccggg 10500
agcagacaag cccgtcaggg cgcgtcagcg ggtgttggcg ggtgtcgggg cgcagccatg 10560
accagtcac gtagcgatag cggagtgtat actggcttaa ctatgcggca tcagagcaga 10620
ttgtactgag agtgccacat atgcggtgtg aaataccgca cagatgcgta aggagaaaat 10680
accgcatcag gcgctcttcc gcttcctcgc tactgactc gctgcgctcg gtcgttcggc 10740
tgcggcgagc ggtatcagct cactcaaagg cggtaatacg gttatccaca gaatcagggg 10800
ataacgcagg aaagaacatg tgagcaaaag gccagcaaaa ggccagggaac cgtaaaaagg 10860
ccgctgtgct ggcgtttttc cataggctcc gccccctga cgagcatcac aaaaatcgac 10920
gctcaagtca gaggtggcga aacccgacag gactataaag ataccaggcg tttccccctg 10980
gaagctccct cgtgcgctct cctgttccga ccctgccgct taccggatac ctgtccgcct 11040
ttctcccttc gggaagcgtg gcgctttctc atagctcacg ctgtaggat ctcagttcgg 11100
tgtaggtcgt tcgctccaag ctgggctgtg tgcacgaacc ccccgttcag cccgaccgct 11160
gcgccttata cggtaactat cgtcttgagt ccaaccgggt aagacacgac ttatcgccac 11220
tggcagcagc cactggtaac aggattagca gagcgaggta tgtaggcggg gctacagagt 11280
tcttgaagtg gtggcctaac tacggctaca ctagaaggac agtatattggg atctgcgctc 11340
tgctgaagcc agttaccttc ggaaaaagag ttggtagctc ttgatccggc aaacaaacca 11400
ccgctggtag cgggtggtttt tttgtttgca agcagcagat tacgcgcaga aaaaaaggat 11460
ctcaagaaga tcctttgatc ttttctacgg ggtctgacgc tcagtggaac gaaaactcac 11520
gttaagggat tttggctcatg catgatatat ctcccaattt gtgtagggct tattatgcac 11580
gcttaaaaaat aataaaagca gacttgacct gatagtttgg ctgtgagcaa ttatgtgctt 11640
agtgcatcta atcgcttgag ttaacgcggg cgaagcgcg tcggcttgaa cgaatttcta 11700
gctagacatt atttgccgac taccttgggt atctcgctt tcacgtagtg gacaaattct 11760
tccaactgat ctgcgcgca ggccaagcga tcttcttctt gtccaagata agcctgtcta 11820
gcttcaagta tgacgggctg atactgggcc ggcaggcgct ccattgccca gtcggcagcg 11880

```

V082.ST25.txt

```

acatccttcg gcgcgatttt gccggttact gcgctgtacc aaatgcggga caacgtaagc 11940
actacatttc gctcatcgcc agcccagtcg ggcggcgagt tccatagcgt taaggtttca 12000
tttagcgctt caaatagatc ctgttcagga accggatcaa agagttcctc cgccgctgga 12060
cctaccaagg caacgctatg ttctcttgct tttgtcagca agatagccag atcaatgtcg 12120
atcgtggctg gctcgaagat acctgcaaga atgtcattgc gctgccatc tccaaattgc 12180
agttcgcgct tagctggata acgccacgga atgatgtcgt cgtgcacaac aatggtgact 12240
tctacagcgc ggagaatctc gctctctcca ggggaagccg aagtttcaa aaggtcgttg 12300
atcaaagctc gccgcgttgt ttcataagc cttacggtca ccgtaaccag caaatcaata 12360
tcactgtgtg gcttcaggcc gccatccact gcggagccgt acaaattgac ggccagcaac 12420
gtcggttcga gatggcgctc gatgacgcca actacctctg atagttgagt cgatacttcg 12480
gcgatcaccg cttcccccat gatgtttaac tttgttttag ggcgactgcc ctgctgcgta 12540
acatcgttgc tgctccataa catcaaacat cgaccacgga cgtaacgcgc ttgctgcttg 12600
gatgcccagag gcatagactg taccctaaaa aaacatgtca taacaagaag ccatgaaaac 12660
cgccactgca cgtttaccac cgtgcgttc ggtcaagggt ctggaccagt tgcgtgacgg 12720
cagttacgct acttgcatta cagcttacga accgaacgag gcttatgtcc actgggttcg 12780
tgcccgaat 12789

```

```

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> degenerate primer ALGG39

```

```

<220>
<221> misc_feature
<222> (3)..(3)
<223> Inosine

```

```

<220>
<221> misc_feature
<222> (9)..(9)
<223> Inosine

```

```

<220>
<221> misc_feature
<222> (11)..(11)
<223> Inosine

```

```

<220>
<221> misc_feature
<222> (15)..(15)
<223> g or a

```

```

<220>
<221> misc_feature
<222> (18)..(18)

```

V082.ST25.txt

<223> any base

<400> 10
ccargykcag gaaaracnac

20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence<220>
<223> degenerate primer ALGG40<220>
<221> misc_feature
<222> (3)..(3)
<223> Inosine<220>
<221> misc_feature
<222> (15)..(15)
<223> any base<220>
<221> misc_feature
<222> (18)..(18)
<223> any base<400> 11
acackyttyt tytgnccncc

20

<210> 12
<211> 8
<212> DNA
<213> Artificial Sequence<220>
<223> degenerate primer ALGG41<220>
<221> misc_feature
<222> (6)..(6)
<223> any base<220>
<221> misc_feature
<222> (5)..(5)
<223> g or a<220>
<221> misc_feature
<222> (3)..(3)
<223> any base<400> 12
tcnarncc

8

<210> 13

V082.ST25.txt

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> degenerate primer ALGG42

<220>
<221> misc_feature
<222> (3)..(3)
<223> Inosine

<220>
<221> misc_feature
<222> (6)..(6)
<223> Inosine

<220>
<221> misc_feature
<222> (9)..(9)
<223> Inosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> Inosine

<220>
<221> misc_feature
<222> (15)..(15)
<223> any base

<220>
<221> misc_feature
<222> (18)..(18)
<223> any base

<400> 13
ggagtaytaa cagcnytnat ggg

23

<210> 14
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> degenerate primer ALGG43

<220>
<221> misc_feature
<222> (3)..(3)
<223> any base

<220>
<221> misc_feature
<222> (18)..(18)
<223> any base

<220>

V082.ST25.txt

<221> misc_feature
<222> (5)..(5)
<223> g or a

<220>
<221> misc_feature
<222> (21)..(21)
<223> g or a

<220>
<221> misc_feature
<222> (12)..(12)
<223> Inosine

<220>
<221> misc_feature
<222> (15)..(15)
<223> Inosine

<400> 14
tcnarcacatcc aagtagcngg rtt

23

<210> 15
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> degenerate primer ALGG44

<220>
<221> misc_feature
<222> (6)..(6)
<223> g or a

<400> 15
ckccarta

8